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INTRODUCTION
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ALZHEIMER DISEASE 
 
 
 
 
Alzheimer disease (AD) is a progressive degenerative disease of the brain that is 
characterized by neocortical atrophy, neuron and synapse loss, and the presence of 
extracellular senile plaques and intracellular neurofibrillary tangles (NFTs) (Fig. 1). The 
primary clinical manifestation of AD is a profound global dementia that is marked by 
severe amnesia with additional deficits in language, “executive” functions, attention, 
and visiospatial and constructional abilities. 
 
Fig. 1. Neurofibrillary Tangles and Amyloid Plaques 
 
 
 
The neurodegenerative changes occur primarily in the hippocampus and entorhinal 
cortex and in the association cortices of the frontal, temporal, and parietal lobes (Fig. 2). 
Although the temporal progression of the neuropathological changes of AD is not fully 
known, recent studies suggest that the hippocampus and entorhinal cortex are involved 
in the earliest stage of the disease, and that frontal, temporal, and parietal association 
cortices develop pathology as the disease progresses. This “spreading” of the pathology 
from those regions of the brain in which hallmarks of the disease (amyloid plaques, 
reactive gliosis, NFTs) can be first detected, to other regions of the brain is notable, and 
 3
while generally accepted as being a genuine feature of the pathology, no explanation for 
it has yet emerged. 
 
Fig. 2. Neurodegenerative changes in Alzheimer Disease brain patients 
 
 
As the population ages, the projected number of individuals that will be affected by 
dementia, and AD in particular, indicates that a serious public health problem is 
looming. However, intense research over the past decade has begun to uncover some of 
the cell and molecular processes leading to neuronal loss with the discovery of possible 
targets for therapeutic intervention, raising the hope that we may be able at least to halt 
the progression of the disease.1  
Diagnosis of AD is based on clinical features which are confirmed by brain 
hystopathological evidence. There are three clinical stages in AD progression,  mild, 
moderate and severe. They are associated with progressive decline of cognitive and 
physical functionalities over 5 – 8 years. The initial stage usually lasts 2 – 3 years and is 
characterized by short-term memory impairment often with symptoms of anxiety and 
depression. In the moderate state these symptoms appear as visual hallucinations, false 
beliefs and reversal of the sleep cycle.2  
At present there is no definitive treatment or cure for AD. 
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ALZHEIMER DISEASE GENETICS 
 
In AD, three genes have been clearly identified as causative and one gene as a risk 
factor. Major clues came from families suffering from autosomal dominant, early onset 
forms of AD (familial AD or FAD). Other than the fact that FAD is clearly hereditary 
and manifests itself at earlier ages (<60 years), it is indistinguishable from the sporadic 
form of AD (with respect to behavioral patterns, disease progression, plaque deposition, 
tangle formation). 
The first identified FAD-causing mutations were found in the gene encoding the 
amyloid-‚ precursor protein (APP) on chromosome 21. At least five such mutations 
have been identified. These are found near the proteolytic cleavage sites in APP that 
result in Aβ, and all lead to increased production of Aβ  in general or specifically a 42-
residue form of Aβ (Aβ42) in transfected cells, in transgenic mice, and in the plasma of 
mutant carriers. Two other disease-causing mutations are found within the Aβ‚ region, 
near an alternate proteolytic processing site; however, the resultant mutant Aβ‚ 
aggregates in the cerebral vasculature and causes hereditary cerebral hemorrhage with 
amyloidosis, either with or without features of AD. A related genetic clue that Aβ is 
involved in the early molecular events leading to AD is the fact that all Down’s 
syndrome (trisomy 21) patients invariably develop AD by age 50. Down syndrome 
patients carry an extra copy of the APP gene, located on chromosome 21, and they 
produce more A‚ from birth and develop amyloid plaques as early as age 12. These 
early plaques are of the diffuse kind and contain Aβ42 almost exclusively. Because 
victims of Down syndrome are fated to develop AD at early ages, the observance of 
Aβ42-specific diffuse plaques suggest that these plaques could be the precursors of the 
dense, neuritic plaques found in the AD brain. 
APP mutations, however, account for only about 10% of FAD cases and only 2% of all 
incidences of AD. Most FAD is caused by missense mutations in the genes for 
presenilin-1 (PS1) and presenilin-2 (PS2), located on chromosomes 14 and 1, 
respectively. These genes encode multi-transmembrane proteins, the normal biological 
roles of which were completely unknown upon discovery. More than 70 different 
mutations in the presenilins have been identified that lead to FAD. Virtually all are 
missense mutations, and these are located in various regions of the primary sequence 
(see below). Remarkably, all such mutations analyzed to date lead to specific increases 
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in Aβ42 production, implicating this particular Aβ species in the etiology of AD. 
Considerable effort has gone into identifying genes associated with the more common 
late-onset, sporadic form of AD. Such searching led to the pinpointing of the ApoE 
gene. ApoE is a lipid transport protein that comes in three allelic variants: E2, E3, and 
E4. The ApoE4 allele is a major risk factor for late-onset AD: those who carry one or 
two copies of this allele may not necessarily develop AD, but these carriers are at 
substantially increased risk. As a function of age, the risk increases with the number of 
ApoE4 alleles inherited, with the mean age of onset being some 15 years earlier and the 
incidence of AD 10 times more likely in individuals who inherit two E4 rather than two 
E3 alleles. Inheritance of ApoE2 decreases risk of the disease and increases age of onset 
(i.e., it appears to be a protective factor). Yet some individuals homozygous for E4 
show no AD symptoms in their 90s, illustrating the principle that this allele is a risk 
factor, not a determinant of whether AD will develop. Apparently, the ApoE variants 
differentially affect Aβ deposition and resulting neurodegeneration. A dose-dependent 
increase in the density of neuritic Aβ plaques and vascular Aβ deposits are associated 
with ApoE4. More recently, studies with transgenic mice have demonstrated that apoE 
is required for amyloid formation and glial activation caused by FAD-mutant APP.3 
 
 
PHARMACOLOGICAL TREATMENT OF AD TODAY 
 
There is a prominent loss of cholinergic, noradrenergic, dopaminergic, and GABAergic 
neurons transmission in AD. Neurotransmitter-based treatments with cholinesterase 
inhibitors (ChEls) and N-methyl-D-Aspartate (NMDA) receptor antagonists are now in 
current use. Hence today the treatment of AD is based on a control of symptoms of the 
disease. 
 
Cholinesterase inhibitors. The aim is to enhance the cholinergic neurotransmission. 
This strategy is based on evidences found in AD patients: (1) brain biopsies and 
authopsy have shown that AD patiens have reduced cortical activity of ChAT which is 
the enzyme that synthesizes Ach from choline. (2) There is a loss of cholinergic neurons 
in the nucleus basalis of Meynert and other subcortical nuclei. These large neurons are 
mainly responsible of cerebrocortical cholinergic supply and play an important role in 
mediating attention and learning of new information. Neuropathologic studies have 
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revealed the presence of NFT in these neurons. (3) Furthermore cholinergic antagonists, 
such as scopolamine interfere with learning ability. While cholinergic agonists have 
been found to facilitate learning, which lends support to the important physiologic role 
of acetylcholine in attention and learning. 
ChEls act by slowing the biochemical breakdown of acetylcholine; the result is that 
cholinergic neurotransmission is prolonged. Three ChEls are commonly used to treat 
patients AD: donezepil, rivastigmine, and galantamine (Fig. 3). ChEls are indicated in 
patients with mild to moderate AD, althought some studies suggested a small benefit 
also in patients suffering from more advanced stages of AD. 
 
Fig. 3. Cholinesterase Inhibitors 
 
 
 
Memantine. Overstimulation of NMDA receptors by glutamate is implicated in 
neurodegenerative disorders. Glutamate is the principal excitatory neurotransmitter in 
the brain. Glutamatergic overstimulation may result in neuronal damage and this a 
phenomenon which lead to an excitotoxicity. The exocitotoxicity consists in a neuronal 
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calcium overload and has been implicated in neurodegenerative disorders. Glutamate 
stimulates a number of postsynaptic receptors including the NMDA receptor, which has 
been particularly implicated in memory process, dementia, and the patogenesys of AD. 
Memantine (Fig. 4) is a non-competitive NMDA receptor antagonist and reduces 
glutamatergic exocitotoxicity. Memantine is used in moderate to severe dementia. This 
substance acts with a non competitive NMDA receptor antagonism with a voltage-
dependance and a low-moderate affinity. Memantine have a fast kinetic of 
blocking/unblocking the receptor which is very important, infact other NMDA receptor 
antagonists (es. Ketamine, amantadine) are high affinity compounds with 
neuropsychiatric side effects. Furthermore the fast block/unblock kinetics means that 
memantine sits on the receptor just long enough to prevent pathological activation af the 
glutamate receptors and then quickly goes away when physiological activation of 
glutamate receptors is needed. Hence memantine preserve the normal-physiologic 
activation of NMDA receptors which is required for learning and memory.  
New studies are necessary to establish whether association between memantine and 
cholinergic treatment may represent a complementary or even synergistic strategies in 
AD treatment.2 
 
Fig. 4. NMDA Receptor Antagonist 
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ALZHEIMER DISEASE PATHOLOGY 
 
AD is caracterized pathologically by the presence in the brain of beta-amyloid plaques 
(Aβ), neurofibrillary tangles (NFT), and neuronal loss.  
NFT are aggregated filaments of a protein called τ, and the density of these filaments in 
the brain are related to the severity of dementia. It is unclear why tangles are formed 
and whether tangles are related to plaques formation (some evidences show that Aβ are 
present especially in the end  stage of the disease and they are unique to AD). Besides a 
remarkable rate of NFT are the first sign for identification of a neurologic disorder 
which may not be AD, indeed we can also find these tangles in other neurodegenerative 
disease.2  
The loss of neurons is probably triggered by inflammation around plaques. 
Plaques are composed of Beta-amyloyd tissue (Aβ) which tends to aggregate in 
insoluble forms in the extra-cellular space. Aβ is generated by the proteolytic process of 
the Amyloid Precursor Protein (APP) which is a type 1 transmembrane protein encoded 
by a gene on chromosome 21. APP is expressed in neurons and glial cells in which APP 
is integrated in the ER. The biological functionality of APP is still unknown. 
APP is metabolised by two different pathways: a non amyloidogenic pathway and an 
amyloidogenic pathway (fig. 5). 
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Fig. 5. APP Cleavage and Amyloid Domain  
 
 
 
(a) A schematic representation of the sequential cleavages of APP at the 
β- and γ- sites to generate β-amyloid. (b) The amyloid domain of APP. 
 
 
 
 
In the non amyloidogenic pathway, an α-secretase first cleaves APP between lys16 and 
leu17 (Fig. 5). Two fragments are originated: sAPPα (which is soluble) and αCTF 
(88aa). Then γ-secretase cleaves αCTF to generate P3 ( a protein of 3 Dalton weight) 
and γCTF. APP is processed in this pathway for 90% and the fragments are soluble so 
they are not implicated in the course of the disease. It is  found that sAPPα has a 
neurotrophic and neuroprotective functionalities against deficiency of glucose and 
glutamate toxicity. Furthermore sAPPα stimulates neurons growth and regulates 
synaptogenesis. 
The amyloidogenic pathway also involved two sequential cleavages (Fig. 5). APP is 
first cleaved by a β-secretase to generate a soluble fragment sAPPβ and a membrane 
bound , 99 amino acid residue, C-terminal fragment (C99). C99 is subsequently cleaved 
by γ-secretase to generate the soluble γCTF and two C-terminal variants Aβ40 and 
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Aβ42. Approximately 90% of Aβ produced is Aβ40, but Aβ42is more prone to 
aggregate as fibrils and is the main component of amyloid deposits.2 
Hence pharmacological inhibition of  β- and γ-secretase could provide a targeted 
therapy for the treatment of AD. 
γ-Secretase would appear to be an aspartyl protease like BACE although γ-secretase is 
associated to presenilins 1 and 2 to exert its proteolytic and biological activity. 
Moreover a large number of substrates have been identified for this enzyme such as 
Notch, Delta and Jagged4 which are important for normal biological processes. Hence 
inhibiting γ-secretase may lead to a variety of unwanted side effects, especially if the 
inhibitor was unable to attain high blood-brain barrier permeability and was thus present 
at high concentrations in the periphery. 
  
 
 
 
Β-SECRETASE 
 
 
β- and γ- secretase are the enzymes involved in the amyloidogenic pathway for the 
generation of Aβ. Today there is a great interest in the development of inhibitor drugs 
against β-secretase. A number of factors have encouraged this research line: first of all 
the fact that the activity of β-secretase is an early step in the production of Aβ. 
Furthermore the absence of phenotype in mice devoid of a functional β-secretase gene 
suggests that the inhibition of this protease during clinical treatment is physiologically 
tolerated. 
β-secretase also termed BACE (β-site App Cleaving Enzyme) is new member of the 
pepsin family of aspartyl proteinases. BACE is a type I transmembrane protein, the first 
member of the pepsin family that exist as an integral membrane protein. β-secretase is a 
novel aspartyl –protease of 501 amino acids containing a single transmembrane domain 
near the C-terminus as well as a signal sequence and pro-peptide region at the N-
terminus.  
β-secretase cuts APP at the sequence EVKM*DAEF (the asterisk is pointing out the 
cleavage site). Furthermore a Swedish family showed a double mutation  in the 
sequence of APP in proximity of β-secretase cleavage site (KM to NL). This mutation, 
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which causes a Familial AD in Swedish family3 has allowed to develop a first series of 
BACE-inhibitors which mime the mutated APP sequence. 
BACE is highly expressed in the brain and the gene is located on chromosome 11. A 
homologue called BACE 2 exists in vascularized tissue such as heart, kidney and 
placenta and the gene has been identified on chromosome 21, but little is known about 
the significance of this homologue.2 It has been shown that BACE 1 and BACE 2 
exhibit 52% amino acid sequence identity and 68% similarity, and BACE 2 cleaves 
APP and short peptides in a β-secretase-like manner. However, BACE 2 is not well 
expressed in the brain and this suggests that it may not contribute to the development of 
AD.5 
The first structure of β-secretase was reported by Tang et al. Tang group have 
discovered a potent peptidic BACE inhibitor (OM99-2) (Fig. 6) and have shown an 
1.9Å X-ray crystal-structure of the enzyme with the inhibitor (Fig. 7).  
 
Fig. 6.  Schematic representation of memapsin 2 residues interacting with the 
inhibitor in each sub-sites 
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Fig. 7. X-ray crystal structure of β-secretase bound to inhibitor OM99-2 
 
 
The inhibitor is located in the cleft of the bilobal BACE-structure. 
 
 
This X-ray structure has given research groups vital information about the enzyme 
structure and the nature of protein-ligand interactions, and it has been essential for the 
development of new BACE inhibitors. 
The bilobal structure of β-secretase has the conserved general folding of aspartyl 
proteases with an extensive β-sheet organization. The inhibitor is located in the 
substrate binding cleft between the amino- and carboxy-terminal lobes, and as expected 
the transition-state mimicking hydroxyethyl moiety is coordinated with the two active 
site aspartates (Asp32 and Asp228). As other aspartyl proteases, β-secretase possesses a 
“flap” that partially covers the cleft, and the backbone of the inhibitor is mostly in an 
extended conformation. However, β-secretase does display some structural differences, 
at least compared with pepsin. Four insertions are located on the molecular surface near 
the aminoterminus of the inhibitor, and together these insertions significantly enlarge 
the molecular boundary of β-secretase compared with pepsin. Two other insertions are 
located at the surface near the inhibitor C-terminus. In general, the β-secretase active 
site is more open and accessible than that of pepsin, and most of the hydrogen bond 
interactions between the enzyme and the backbone of the inhibitor are highly conserved 
among eukaryotic and HIV aspartyl proteases. However, the S2 and S4 subsites are 
relatively hydrophilic and open to solvent, and the hydrophilic character of these 
subsites is not conserved in the corresponding subsites of other human aspartyl 
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proteases, such as pepsin, gastricsin, and cathepsins D and E, suggesting that these 
differences could be exploited for the design of selective inhibitors. In contrast, the P3’ 
and P4’ inhibitor side chains OM99-2 point toward the molecular surface and have little 
interaction with the protease. The backbone of residues P2’-P4’ deviates from the 
regular extended conformation, with a kink at P2’, another unusual feature for an 
aspartyl protease that might be turned to advantage in inhibitor design.5 
 
Fig. 8. X-ray crystal structure of β-secretase bound to inhibitor OM99-2 
 
 
Close-up view showing the interaction of the inhibitor hydroxyl group 
with the two catalytic aspartates (yellow). 
 
Asp 32 and Asp 228 lie in the centre of the active site and they  seems to be critical for 
catalytic activity. Mutational studies on HIV-1 protease (an aspartyl protease) have 
shown a complete loss in activity with the removal of either carboxyl.6 
A number of mechanism have been proposed for the proteolytic cleavage of peptides by 
aspartyl proteases. These mechanism are based on X-ray crystal structures, kinetics, and 
general physical organic principles. In general most of the mechanism that have been 
put forward are based on the general acid- general base  theory, and suggest formation 
of a tetrahedral intermediate as a key step in the cleavage of the peptide bond.  It has 
been proposed that the catalytic aspartates have an overall –1 charge, specifically one 
aspartate is protonated and the other one is deprotonated.7,8 Further, a bound water 
molecule in involved in the most proposed mechanism for proteolysis.9 
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Computational  studies using X-ray structures of BACE revealed that the enzyme can 
adopt at least two conformations in binding ligands. An open conformation has been 
identified when BACE is bound with a non-peptidomimetic inhibitor, and a closed 
conformation has been found when BACE is bound with a peptidomimetic inhibitor.10 
One critical issue  in any proper description of the mechanism is the identification of the 
protonation states of the catalytic aspartates, and the location of the protons. Hence 
other computational studies tried to understand the role of the two aspartates around the 
enzymatic activity. These studies have shown that  the monoprotonated form is 
preferred when an inhibitor is bound to the enzyme and specially the protonation of the 
inner oxygen of Asp 228 is preferred  over all other proton location.11 
On the other hand, the most stable protonation state is the di-deprotonated when the 
inhibitor is removed.11  
BACE 1 is found in the endoplasmic reticulum (ER), Golgi network, cell surface and in 
endosomes.12,13 
Furthermore BACE and APP are both endocytosed into endosomes for cleavage. 
Endosomes are likely to be the major site for β-secretase processing because of the 
acidic pH optimum for the enzyme activity. This is quite important in for the design of 
BACE inhibitors. It should be considered that a molecule have to penetrate across at 
least five biological barriers: (i) intestinal membrane when absorbed; (ii) Phase I and II 
metabolic processes, especially in the liver but also in a range of other tissues; (iii) the 
blood-brain barrier when entering the brain; (iv) the cell membrane when reaching the 
site of action, and; (iv) the endosomal membrane when binding to BACE.10 
All of the above characteristics have to be considered to design and develop new 
BACE-inhibtors and goes a long way to explain the poor in vivo results obtained with 
the potent, but non drug-like peptidic and peptidomimetic inhibitors that have been 
studied by many groups. 
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BACE INHIBITORS 
 
 
Many things have to be considered in designing BACE inihibitors: a) The fact that 
BACE is an aspartyl protease with a characteristic catalytic site, b) BACE contains 
subsites (termed exosites) that could regulate the catalytic activity giving more 
possibilities for the inhibitors design, c) the inhibitor have to penetrate the brain barrier, 
hence we need small molecule, d) the inhibitor have to penetrate the cell and especially 
endosomes. BACE inhibitors research is divided in two lines: one concerning 
peptidomimetic structures and one non-peptidomimetic structures. 
 
Peptidomometic inhibitors 
Statines. The statine isostere is derived from the natural product pepstatin, which is a 
potent inhibitor for many aspartyl protease, although not BACE. Tang and Gosh 
proposed peptidominetic statine inhibitors based on the sequence of Swedish-mutant 
APP. OM99-1 and OM99-2 (Fig. 9) have been designed which have shown to be potent 
inhibitors.14 
 
Fig. 9. Statine Isosteres; Gosh and Tang Inhibitors 
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OM99-1 and OM99-2, peptidic inhibitors of seven and eight residues, contained a non-
hydrolysable Leu-Ala based hydroxyethylene dipeptide isostere. Subsequently, detailed 
information on the subsite from X-ray crystal structure of BACE bound to OM99-2,15-17 
lead to the design by Gosh and Tang a more potent inhibitor OM00-3 (Fig. 10) with a 
Ki value of 0.3 nM.18 
 
Fig. 10. Gosh and Tang Inhibitor OM00-3 
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Hydroxymethylcarbonyl isosteres. Hydroxymethylcarbonyl isosteres (norstatine) are 
truncated versions of the common statine transition state mimic. Kiso et al reported a 
series of octapeptides with BACE inhibitory activity. KMI-008 (Fig. 11) have shown an 
IC50 of 413 nM,19 altought the chemical-fisycal characteristics were not suitable as a 
drug due to its large molecular weight, vulnerability to exopeptidases, and the presence 
of many natural peptide bonds. 
 
Fig. 11. Hydroxymethylcarbonyl Isosteres by Kiso group 
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 Then Kiso reported two compounds (Fig. 12) KMI-358 (IC50=16nM) and KMI-370 
(IC50= 3.4 nM) as BACE inhibitors with a smaller molecular weight than KMI-008.20 
 
Fig. 12. KMI-358 and KMI-370 by Kiso group 
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The β-N-oxalyl DAP residue in P4 plays an important role in enhancing the inhibitory 
activity on BACE, but these inhibitors isomerised in acqueous and organic solvent that 
results in lowering the inhibitory BACE activity. Hence, Kiso have tried to solve the 
problem modifying the β-N-oxalyl DAP moiety with a tetrazole carbonyl derivative, 
and two other potent inhibitors were synthesized: KMI-420 (IC50= 8.2 nM) and KMI-
429 (IC50= 3.9 nM) (Fig. 13).21 
 
Fig. 13. KMI-420 and KMI-429 by Kiso group 
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Hydroxyethylene (HE) dipeptide isosteres. In this class of compounds the amide bond 
is replaced by an all-carbon framework and a Hydroxyl group in positioned to engage 
the catalytic aspartates. This type of derivative was used extensively for the 
development of rennin and HIV-protease inhibitors. Gosh and Tang also reported a 
series of compounds with a lower molecular weight than OM99-2. In the new molecules 
P3’, P2’ and P4 were deleted and the P2 side chain was replaced with designed ligand to 
allow hydrogen bonding in the S2 subsite (Fig. 14).22 Some such compounds have 
shown a Ki comparable to that for OM99-2.22 
 
Fig. 14. Gosh and Tang. Hydroxyethylene Dipeptide Isosteres 
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The Elan research group reported their first generation of statine-based inhibitors with 
an hydroxyethylene dipeptide structure. Three compounds have shown interesting IC50 
values in comparison with statine-based inhibitors (Fig.15).23,24 
 
Fig.15. Elan; Hydroxyethylene Dipeptide Isosteres 
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Hydroxyethylamine (HEA) isosteres. The hydroxyethylamine isosteres were widely 
used as aspartyl protease inhibitors, especially they gave the basis for the Amprenavir 
(HIV-protease inhibitor).25 
The Tamamura group have designed and synthesized a range of BACE inhibitors based 
on the hydroxyethylamine dipeptide isostere, and TK-3 have shown a μM inhibitory 
activity against BACE (Fig. 16).26 
 
Fig. 16. Tamamura Group. Hydroxyethylamine Isosteres 
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The Merck research group have recently reported cell permeable BACE inhibitors with 
a low molecular weight containing hydroxyethylamine dipeptide isosteres (fig. 17).27 
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Fig.17. Merck. Hydroxyethylamine Dipeptide Isosteres 
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Carbocyclic and heterocyclic peptidomimetic inhibitors. Recently Hanessian group 
have reported a novel series of peptidomimetic inhibitors where the hydroxyethylene 
subunit of the original OM99-2 was replaced at the P1’ position with a cyclopentane 
ring moiety. In particular a compound (Fig. 18) have shown an IC50 of 25 nM.28 
 
 
Fig. 18. Hanessian group. Carbocyclic Peptidommimetic Inhibitors 
 
 
 
Further, replacement of cyclopentane ring by a cyclopentanone ring resulted in 
enhancement of inhibitory activity in compound reported below (IC50= 10 nM) (Fig. 
19).28 
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Fig.19. Hanessian group. Carbocyclic Peptidommimetic Inhibitors 
 
 
 
 
 
 
 
 
Non peptidomimetic inhibitors 
Piperidines. Piperidine derivatives have shown to be able to inhibit the aspartyl protease 
renin.29-32 X-ray structure of renin  bound to piperidine inhibitors showed that the 
protonated piperidine nitrogen was positioned between the two catalytic aspartates. 
Substituents on the 3-position seemed to fill into the S1-S3 subsites, and the 4-aryl ring 
take up a new binding pocket under the enzyme flap.33  
Several research groups have disclosed patent applications about piperidine as BACE 
inhibitors. A compound have been reported (Fig. 20) by a Vertex patent with a Ki < 3 
μM.34 
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Fig. 20. Vertex. Piperidine Derivatives BACE Inhibitors 
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An Elan patent reported piperidine and other cyclic amines as BACE inhibitors.35,36 
Especially a piperidine compound (Fig 21) have shown a modest BACE inhibitory 
activity (IC50=11 μM) 
 
Fig. 21. Elan. Piperidine Derivatives BACE inhibitors 
 
 
 
 
Furthermore from Actelion 3-/4- aminomethyl piperidines and 3-/4- aminopiperidines37 
were disclosed (Fig. 22).38 
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Fig. 22. Actelion. Piperidine BACE inhibitors 
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The De Novo group has described a series of piperazine inhibitors exemplified by 
compound in Fig. 23 IC50=3 μM.39 
 
Fig.23. De Novo group. Piperazine Derivatives BACE inhibitors 
 
 
 
 
Miscellaneous chemotypes. Natural substances and other small molecule have been 
reported as BACE inhibitors.  
(-) Epigallocatechin gallate (Fig. 24) has shown to be the most potent inhibitor of BACE 
with an IC50 of 1.6 μM. It is also non-competitive with substrates.40 
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Fig. 24. (-) Epigallogallocathechin gallate 
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Genetics company performed a pharmaco-phore search starting from the crystal 
structure of OM99-2 bound to BACE and reported several new classes of inhibitors 
(Fig. 25).41 
 
Fig. 25. Genetics Company BACE Inhibitors 
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Takeda research group disclosed trisubstituted long chain-amines with more than one 
aromatic ring in the chain, in particular a tetralin compound (Fig.26) have shown an 
inhibitory activity of 250 nM on BACE.42 
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Fig. 26. Takeda group. Tetralin Derivatives BACE inhibitors 
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CHOLESTEROL AND AD……IS THERE A CONNECTION? 
 
Research over the last 10 years has revealed some correlations between yholesterol and 
the Alzheimer’s disease. It is increasingly recognized that coronary artery disease,43 
hypertension,44 atherosclerosis,45 diabetes,46 hypercolesterolemia47 increase the risk for 
the AD onset.  
Cholesterol is a necessary component of  all cell membranes and is important both as a 
structural component and as a modulator of cell fluidity. Cholesterol is synthesized in 
the body  and it is also obtained through the diet from animal products. Cholesterol is 
carried in the blood on lipoproteins which are divided in different classes: 
chylomicrons, very-low density lipoproteins (VLDL), intermediate-density lipoproteins 
(IDL), low-density lipoproteins (LDL),  and high density lipoproteins (HDL). 
The association of cholesterol with dementia may vary depending upon when 
cholesterol is measured in the life-span and/or relative to the course of the disease. High 
cholesterol may be a risk factor if measured in mid-life many years before clinical 
onset, but as the disease pathology progresses cholesterol levels may fall such that it 
appears that high cholesterol is protective. 
APOE has been identified as a major risk gene for AD, including sporadic AD. The 
APOE gene codes the apolipoprotein E, which has several important functions: it 
transport lipids between cells,48 is critical for the coordination of cholesterol in the 
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repair, growth, and maintenance of myelin and neuronal membranes during 
development or after injury.49 
APOE gene exists in three isoforms: ε2, ε3, ε4. Normally, the ε3 allele is the most 
common followed by the ε4 allele.50 Several studies have shown that inheritance of the 
APOE ε4 allele is associated with elevated cholesterol levels and an increased risk of 
developing AD compared to individuals with only the APOE ε2 or APOE ε3 alleles.51-53 
Although the mechanism behind the contribution pf APOE ε4 to an increased AD risk is 
currently unknown. 
There is the idea that statines  could have a role in decreasing the risk of AD. Statines 
inhibit HMG (hydroxyl-3-methyl-glutaryl-CoA)54 which is involved in cholesterol 
synthesis. The  result of inhibiting this enzyme is a decrease of LDL levels and an 
increase of HDL levels. Recent studies have shown that reduction in cholesterol levels, 
due to the statines effect, increases the non amyloidogenic α-secretase activity55 and 
decreases BACE activity perhaps with an inhibiting mechanism.56  
However the research in this field is in its infancy and further rigorous studies to reveal 
the real relationship between cholesterol and AD risk and precise regulation 
mechanisms are required. 
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THE AIM OF THE THESIS 
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This PhD thesis has been carried out in collaboration with Siena Biotech. The aim of 
this work concerns the design and synthesis of novel active molecules in Alzheimer 
Disease therapy. 
Alzheimer’s Disease (AD) is characterized by the production in the brain of 
extracellular amiloyd plaques composed largely of the β-amyloid peptide (Aβ). Genetic 
evidence obtained from familial forms of AD suggests that up-regulation of the 
production of the 42 amino-acid form of Aβ has a primary role in the disease. The Aβ 
peptides are generated by successive cleavages of the amyloid precursor protein (APP) 
by β- and γ-secretases, both of which have emerged as strong therapeutic targets for AD 
intervention. Our work focused the attention on β-secretase (BACE) which is an 
aspartyl protease and it is responsible for the initial cleavage of APP.  
This PhD work has been developed around the research of new non peptidic BACE 
inhibitors. Small molecules, which can penetrate blood brain barrier, have to be found 
in order to reach the action site and regulate Aβ production and aggregation. 
In particular, the work reported in this thesis deals with the research of non peptidic 
compounds with low molecular weight, good stability and good bio-availability. 
This PhD work started with the analysis of issued patent disclosing BACE inhibitors. 
Looking at the literature we found a considerable number of patents and other 
publications, brought out by well-known companies, disclosing structures that inhibit 
BACE. A large number of peptidic and non peptidic structures have been reported. 
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In particular, we focused our attention on Elan, Actelion and Takeda patents that 
disclosed non peptidic structures with BACE inhibitory activity in the μM range (Fig. 
27). 
 
Fig. 27. Patented BACE inhibitors 
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This research work has been divided in four parts:  
 
Synthesis of patented compounds: Compounds 1 and 4 (Fig. 27) have been re-
synthesised and then taken as model for the next studies. 
 
3-Aminopiperidine Derivatives: Looking at the Elan (1) and Actelion (2) structures (Fig. 
27) we have designed a new piperidine scaffold, which is an hybrid of the two patented 
molecules, trying to blend the two patented structures with some modifications. Two 
series of compounds A and B have been carried out from this work (Fig. 28). 
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Fig. 28.  3-Amino piperidine derivatives 
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In both series of compounds we have introduced a single substitution on piperidine ring 
in position 3 which is characterized by a nitrogen atom bearing aryl groups widely 
substituted (R’, R’’), and by a carboamido (A series) or a sulfonamido (B series) 
moiety. As concerning endocyclic nitrogen piperidine we have introduced a substituent 
R that may be an hydrogen atom, a Boc group, or a phenyl-acetyl group. 
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Analogue of Takeda Tetralin Derivatives: Based on structure 3 disclosed by Takeda 
group a new compound 5 (Fig. 29) has been designed and synthesised.  
 
Fig. 29. Tetralin Derivative 
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The aim of this work was to create a new molecule with more polar characteristics than 
the referring Takeda disclosed compound 3. Hence in compound 5 tetralinic moiety has 
been replaced with benzodioxane, and piperidine group has been substituted with 
dimethylamino group. 
 
Carbazole Derivatives: In order to find new classes of potential hits as BACE inhibitors 
a random and focused screen of commercially available compounds was carried out at 
Siena Biotech. One of the hit classes identified was a series of carbazole derivatives. 
They found that  some carbazole derivatives (fig. 30) showed inhibitory activities on 
BACE ranging between 1 and 10 μM. 
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Fig. 30. Screened carbazole derivatives 
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Inspired by screened compounds 6, 7 and 8 five series of molecules came out. Two first 
series C and D (Fig. 31) were based on a carbazolic structure 6 and 7, where R’ and R’’ 
are aryl group widely substituted and X may be a carboamidic (C series) or a 
sulfonamidic (D series) moiety. 
 
Fig. 31. New carbazole derivatives: C, D series 
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Compound 6 and 7 also ispired two other series of new molecules: indole derivatives 
and tetrahydrocarbazole derivatives (Fig.32). We have proposed a sulfonamidic 
structure where carbazole group was substituted with an indole (E series) and a 
tetrahydrocarbazole (F series). 
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Fig. 32. New carbazole derivatives: E, F series 
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Finally screened compound 8 gave the start for the last series of  β-naphtylaminic 
derivatives (G series) where we wanted to explore the activity of naphtylaminic 
compounds making modification around 3,6-di-Bromo-carbazolic moiety (Fig. 33). 
 
Fig. 33. β-naphtylaminic derivatives: G series 
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All the synthesised compounds have been tested on BACE at highest concentration of 
20 μM with a time-resolved quenching assay developed at Siena Biotech laboratories in 
order to evaluate a possible BACE inhibitory activity. 
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SYNTHESIS OF PATENTED COMPOUNDS 
 
In the first part of this PhD work we have been interested in the synthesis of patented 
compounds 1 and 4 (Fig. 34) in order to take their strucuture as model for the next 
studies. 
 
Fig. 34. Patented Elan and Actelion compounds 
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Patented synthesis and adapted strategies have been followed for the synthesis of these 
compounds.    
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Synthesis of compound 1  : 
The original patent37 described a well-constructed synthesis which would have involved 
many steps showing disadvantages in term of yields. Moreover, it would have started 
from a non commercially available compound which would have to be synthesised from 
appropriate precursors without clear literature references reported in the patent (Fig 35).  
 
Fig. 35 Original patented synthesis 
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Therefore, we planned a novel synthetic pathway (scheme 1) referring to literature and 
well known procedures also improved in our laboratories. 
 
 
 
 
A Grignard reaction with phenylmagnesium bromide has been made on the 
commercially available N-benzyl-4-piperidone 9. After one night the reaction afforded 
compound 10 with a good yield (99%). Compound 10 has been dehydrated with a 20% 
solution of H2SO4 in CH3COOH to obtain olefine 11. After purification by flash 
chromatography olefine 11 has been submitted to an oxidative hydroboration with a 
boron-DMS complex. The reaction afforded alcool 12 where the hydroxyl group has 
been introduced into the 3 piperidine position, trans with respect to the phenyl group. 
Alcool 12 has been purified by flash chromatography (yield 68%). A traditional method 
for esterification reaction has been done to obtain compound 13. 
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Scheme 1. Compound 1 Synthesis  
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Hence alcool 12 has been treated with 4-biphenyl-carbonyl-chloride in the presence of 
Et3N as the base, and DMAP as the catalyst. Subsequently, final product 1 has been 
obtained by a catalytic hydrogenation. Compound 13 has been dissolved in EtOH and 
CH3COOH under a H2 atmosphere with 10% Pd on carbon. The desired compound 1 
has been obtained with a 80% yield after purification by flash chromatography. 
 38
 
synthesis of compound 4: 
Original patented reaction conditions57 have been mainly followed for compound 4. The 
synthesis has been shown in scheme 2. 
 
Commercially available N-Boc-L-Lysine 14 has been treated with benzylchloro 
formiate in a 2N NaOH solution to protect the free amine group. After 2 hours the 
reaction afforded the desired product 15 in good yields. Hence, the carboxyl moiety has 
been protected with a benzyl group by reaction with benzyl-bromide in DMF as solvent. 
The desired product 16 has been purified by flash chromatography and a yellow oil has 
been obtained (87% yield). Reaction for 2 hours with a solution of trifluoroacetic acid 
has cleaved the Boc group and afforded compound 17. 
The amine group has been functionalised, first with an isobutyl moiety by a reductive 
amination (compound 18) and then with a sulfonamidic moiety through  reaction with 
the 4-nitrobenzensulfonyl chloride in classical sulfonylation method (compound 19). An 
overnight catalytic hydrogenation, with 0.1 equivalent of Pd, should have reduced the 
nitro group to an amino group, and subsequently released the carboxyl moiety and the 
amine protected with the benzyl group. These conditions, reported in the patent did not 
lead to the desired product 21, but to a compound where only the nitro group had been 
reduced with no removal of the Cbz and benzyl groups (compound 20).In this case we 
have optimised reaction conditions increasing Pd quantity to 0.4 eq and also increasing 
reaction time to 4 days. In this way the catalytic hydrogenation led to the desired 
product 21 with a 65% yield. The last step was the introduction of fluorenyl group by 
reaction with the Fmoc-chloride and a mixture 1:1:1 of  2N aq K2CO3, THF and 
CH3CN. Final product 4 has been obtained in 44% yield. 
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Scheme 2. Compound 4 Synthesis 
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3-AMINO-PIPERIDINE DERIVATIVES 
 
The second part of this thesis is based on the study of patented compounds from Elan 37 
and Actelion39 patents (Fig.36). We started from the fact that compounds 1 and 4 (Fig. 
36) showed some structural analogies: piperidine, bi-phenyl, and aryl groups are 
represented in both structures. 
 
Fig. 36. Compounds from Elan and Actelion patent 
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In order to analyse spatial disposition of these three common pharmacophoric groups, a 
theoretical study has been performed in Siena Biotech. Viewer Pro Program was used to 
create a superimposition of  referring structures from Elan an Actelion patents (Fig. 37). 
Compound alignment was carried out using Accelrys DS Pro software. Putative 
common features were first tethered and a flexible overlay carried out. Subsequently the 
molecules were minimised prior to a second rigid overlay to give the alignment 
hypothesis shown in. The resulting 3D model obtained from the program allowed us to 
analyse in detail the spatial conformation of   disclosed reference compounds and their 
structural analogies. 
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Fig. 37. Comparison of the Actelion (green) and Elan (grey) molecules 
 
 
 
 
 
 
 
 
 
 
 
 
Superimposition was obtained by fitting the piperidine nitrogen of two reference 
compounds, and  Heteroatoms are coloured by atom type (N blue, O red). 
 
 
From the spatial superimposition of the two compounds we can observe that i) the two 
piperidine rings are aligned; ii) the two biphenylic groups of two referring compounds  
efficiently superimpose in spite of the fact that  they are in different positions inside the 
original molecules; iii) the phenyl ring of compound from Elan patent resulted aligned 
to the benzoyl one of the compound from Actelion patent, albeit in the first one this 
scaffold  is directly linked to the piperidine ring and in the second one is sensitively far 
away. 
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Fig. 38. Carbazole derivatives: C, D series 
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Looking at the Elan and Actelion structures (1 and 4) two new series of hybrid 
piperidine scaffold A and B (Fig.38) have been designed trying to blend the two 
patented structures with some modifications. We have introduced a single substitution 
on piperidine ring in 3 position which is characterized by a nitrogen atom bearing 
variously substituted (R’, R’’) aryl groups; in A series a carboamido moiety and in B 
series a sulfonamido moiety were synthesised. As concerning nitrogen piperidine it may 
be unsubstituted, or we have introduced a substituent R that may be a Boc group, or a 
phenylacetyl group. 
For the synthesis of this compounds (Fig. 3) a methodology of solid phase synthesis,  
parallel synthesis and parallel purification has been adopted. Thanks to a collaboration 
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with Siena Biotech it has been possible to learn this new methodologies and, a large 
number of compounds have been easily synthesised.  
 
Scheme 3.  A Series  synthesis: 
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Scheme 3a. A Series Synthesis 
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Commercially available 3-Amino piperidine (Scheme 3) has been treated with the 
respective aldehydes to obtain amines 23-26. The reaction gave good yields for the 
aldehydes (> 90%) and the products have been purified by ionic exchanged pre-packed 
silica columns, which are specific for purification of  molecules which have basic 
moieties. The second step for the synthesis of 3-amino piperidines (A series) was the 
acylation of amines 23-26 with the R’’ aryl-acyl-chlorides. In this reaction PS-DIEA 
was used to neutralise the reaction mixture. PS-DIEA is dimethyl-isopropyl-ethyl amine 
which is supported on poly-styrene. This resin captured HCl that was released during 
the reaction and remained in a solid state. Hence we had got rid of it by filtration, 
avoiding problems of purification. Purification of compounds A1-A7 has been carried 
out with pre-packed silica gel columns. Boc-clevage (Scheme 3a) has been done by 
reaction of compounds A1-A2 with a solution of TFA in CH2Cl2. The reaction was 
completed in 2 hours and led to the desired compounds (A8-A9) generally in good 
yields. Both compounds A8 and A9 have been purified with ionic exchanged pre-
packed columns. The last step was the acylation of  compound A9 at piperidinic 
nitrogen with a phenyl-acetyl group (Scheme 3b). Reaction conditions have been the 
same of the acylation in step two with good yields for compound A10. 
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Synthesis for B series (Scheme 4 and 4a) was similar to that of the same of A series, and 
it started from amines 23-26 obtained as described in scheme 3. 
 
Scheme 4.  B Series  synthesis 
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Scheme 4a. B series Synthesis 
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Amines 23-26 was submitted to sulfonylation with the R’’ aryl-sulfonyl-chlorides 
(compounds B1-7). The outcome of step two was not the same for acylation or 
sulfonylation in series A and B,  and generally we obtained the best result and yields 
with sulfonyl reagents (TLC have shown a clearer reaction mixture in sulfonyl reactions 
than acyl chlorides ones). The purification for compounds B1-B7 has been carried out 
with pre-packed silica column.  
Boc-clevage (Scheme 4a) has been done by reaction of compound B1 with a solution of 
TFA in CH2Cl2. The resulting compound B8 has been purified with ionic exchanged 
pre-packed silica columns. 
 The last step (Scheme 4a) was the acylation of  compound B8 at piperidinic nitrogen 
with a phenyl-acetyl group. Reaction conditions have been the same of the acylation, 
with PS-DIEA DMAP and CH2Cl2, with good yields for compound B9.  
 
 
 
 
RESULTS and DISCUSSION 
Series A and B compounds have been shown in table 1 and 2 and percentage of BACE 
inhibition have been reported. All synthesised compounds have been tested on BACE 
with a time-resolved fluorescence quenching assay at the highest concentration of 20 
μM.  
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Table 1.   Type A Compounds 
N
N
R
O
R'
R''
A  
 
Compound R R’ R’’ % inhibition 
A1 Boc H 4-Ph No activity 
A2 Boc 4-Ph H 27 
A3 Boc 4-Ph 4-Ph No activity 
A4 Boc 4-Ph 2,4-Cl 32 
A5 Boc 4-Ph 4-F 29 
A6 Boc 2-Ph H No activity 
A7 Boc 3-Ph H No activity 
A8 H H 4-Ph No activity 
A9 H 4-Ph H No activity 
A10 
O
 
4-Ph H No activity 
 
 
Type A Compounds:  In A series, as concerns R group on nitrogen piperidine atom, Boc 
cleavage led to a loss of activity (A8, A9), moreover the substitution with a 
phenylacetyl group (A10) showed again no inhibitory activity on BACE. Results in 
Table 1 also showed that when benzylamine group was unsubstituted (R’=H) no BACE 
inhibitory activity have been reported (A1, A7). A percentage of inhibition on BACE 
came out when a phenyl group was introduced in position 4- on the benzylaminic 
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moiety (A2); whereas, if a phenyl group is simultaneously introduced in position 4- of 
the two aromatic portions (R’= R’’= 4-Ph) we found a loss of activity (A3). Halogen 
atom R’’ introduction into the benzenecarbonyl position is tolerated (A4, A5). A loss of 
activity is also reported shifting phenyl group R’ in position 2- or 3- on benzylaminic 
moiety (A6, A7).  
 
Table 2.  Type B Compounds 
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Compound R R’ R’’ % inhibition 
B1 Boc H 4-Ph No activity 
B2 Boc 4-Ph H 30 
B3 Boc 4-Ph 4-Ph 40 
B4 Boc 4-Ph 2,4-Cl No activity 
B5 Boc 4-Ph 4-F No activity 
B6 Boc 2-Ph H No activity 
B7 Boc 3-Ph H No activity 
B8 H H 4-Ph No activity 
B9 
O
 
H 4-Ph No activity 
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Type B compounds: In B series, just like in A series,  no BACE inhibitory activity was 
found when piperidine nitrogen atom was not substituted (B8). The introduction of a 
phenyl-acetyl group (R) on piperidine ring (B9), led to a loss of BACE inhibitory 
activity. Furthermore, we found again that BACE inhibition is preserved when a phenyl 
substitution was on position 4- benzylaminic moiety (B2). Whereas, in this case a 
simultaneously introduction of 4-phenyl on both aromatic substituents is tolerated (B3). 
Contrairly to A series, in B series we found a loss of activity when halogen atom was 
introduced as R’’ on phenyl sulfonamidic group (B4, B5). Once again, shifting phenyl 
group R’ from 4- to 2- or 3- position on benzylaminic moiety, a loss of activity was 
reported (B6, B7).  
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ANALOGUE OF TETRALIN DERIVATIVES 
 
 
Research of tetralin derivatives has been based on a detailed study of  Takeda patent 42 
where the key compound 3 has been reported to inhibit BACE with an IC50 of 0.35 μM 
(Fig. 39). 
 
Fig. 39. Patented compound by Takeda group 
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In this study, the patent has been analysed in detail to examine all disclosed structures 
reported. This analysis showed that lateral moieties of the the general formula (Fig. 40), 
Ar, X, Y and amine group were mainly explored, whereas central moiety AB (circled in 
red) did not cover many disclosed structures. In fact, we found that central core could be 
only a tetralin, a 1,2 dihydronaphthalene, or a tetrahydroquinoline. (Fig. 40). 
 
 
 
 
 
 
 
 
 
 
 
 51
Fig. 40. Central cores disclosed in Takeda patent 
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Hence, we planned to work on possibile replacements of the central cores reported in 
the patent. The idea was to insert in this central core heterocyclic moieties in order to 
increase the Takeda molecules polarity. Infact, this compound has shown an interesting 
BACE inhibitory activity, but his high lipophilicity could be a problem in his 
development because of a predicted poor oral bioavailability. 
Looking for new heterocicles a large number of structures have been designed with  
new central cores.  
Furthermore another patented structure (27) reported by takeda has been considered 
(Fig. 41). This molecule was less active on BACE (IC50= 2.93 μM) but it was a little 
more polar than compound 3 because of the presence of dimethylamine instead of 
piperidine. 
 
 
 
 
 
 
 
 
 
 52
Fig. 41. Tetralin structure reported by Takeda group 
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Approximately a hundred structures, unprecedented in the literature, have been designed 
related to the referred takeda compounds. All new molecules contain different central 
cores from compounds disclosed by Takeda group. Lateral chain was reduced to a 
methylene group instead of an ethylene, as reported in patented compounds 3 and 27. 
This modification should help in reducing polarity of the new molecule, and besides, in 
Takeda patent structures with shorter lateral chain were also reported. Furthermore, 
looking across literature references, we have seen that a shorter lateral chain , with only 
a methylene, was synthetically more accessible to introduce than the ethylene.  
New designed structures, hence, have been submitted to a theorical study based on 
Lipinsky, Veber and Norinder’s rules. This study, based on predicted theoric calculus, 
allowed us to select 7 structures (Fig. 42) with the best physico-chemical characteristics 
to penetrate the Blood-Brain Barrier. 
In this study, all the designed molecules have been evaluated on the base of restrictions 
of the three  most important parameters for a  good bio-availability for CNS: RBN 
(number of rotatable bonds), MlogP (parameterization of the hydrophobicity) and BBB 
(blood-brain barrier permeability) were made to their optimum value in order to obtain 
compounds with better predicted physicochemical properties. 
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Fig. 42. New structures related to Takeda disclosed compounds 
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Based on this results a further selection has been done considering the synthetic 
accessibility of these new compounds. Therefore, a 1,4-benzodioxanic compound (5) 
has been sorted out as the best candidate for our synthetic work (Fig. 43). 
 
 
 
 
 
 
 
 
 
 
 54
Fig. 43. 1,4-benzodioxanic structure 
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Central core for compound 5 was a 1,4-benzodioxane moiety that should give to the 
molecule a higher polar characteristics than referring Takeda compounds (3, 27) due to 
the presence of two oxygen atoms in the central core and a dimethylamine group instead 
of piperidine group on the lateral chain.  
Synthetic pathway for compound 5 has been carried out according to literature and 
Takeda patent (Scheme 5). 
 
 
 
Commercially available 4-benzyloxy-2-hydroxy-benzaldehyde 28 was treated with 
epichloridrine to obtain aldehyde 29 58. Aldehyde 29 was reduced submitted to a Bayer-
Villiger oxidation to an instable formiate intermediate that spontaneously produced 
phenol 30 (59). Phenol 30 was converted to the 1,4-benzodioxane by cyclization in 
KOH 2N (compound 31) (58). A catalytic reduction with Pd/C 10% afforded compound 
32 with free phenol group. Hence, we have introduced a bi-phenyl group by reaction 
with 4-phenylbenzyl chloride in CH3CN (compound 33). The subsequent 
transformation of primary alcol into a iodide by reaction with imidazole, iodine and 
triphenyl phoshine (compound 34) 42, allowed us to introduce subsequently a di-
methyalmine group to obtaine final desired product 5 42. Compound 5 has been treated 
with Et2O·HCl to achieve its hydrochloride salt form 5·HCl (17% yield). 
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Scheme 5. Compound 5 Synthesis 
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RESULTS and DISCUSSION 
 
 
Compound 5 has been tested on BACE with a time-resolved fuorescence quenching 
assay. In spite of the general structure which closely resembled patented compounds 3 
and 27, with the exception of the introduction of oxygen atoms in the central core and of 
the lateral chain cut, unfortunately, compound 5 did not shown any significant 
inhibitory activity on BACE.  
 
Table 4. Tetralin Derivatives Results 
 
Compound Structure IC50 (μM) 
3 O
N
 
0.35 
27 O
N
 
2.93 
5 
O
O
N
O
 
> 10 μM 
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CARBAZOLE DERIVATIVES 
 
In order to find new classes of potential hits as BACE inhibitors a random and focussed 
screening of commercially available compounds was carried out at Siena Biotech. One 
of the hit classes identified was a series of carbazole derivatives, some of which showed 
inhibitory activities on BACE ranging between 1 and 10 μM (Fig 44).  
 
Fig. 44. Screened carbazole derivatives 
 
N
OH
N
SO2
R
N
OH
N
H
Br
Br
8
6   R= H
7   R= CH3  
 
 
We then envisaged the possibility of a new series of BACE-inhibitor compounds related 
to these carbazolic structures.  
Some computational studies on compound 6 have been carried out in Siena Biotech to 
giustify the activity with a possible interaction between carbazole derivatives and 
BACE on the basis of β-secretase catalytic site.  
In the protease family the binding site is usually mapped using a sub-pocket 
organization. The binding site (Fig. 45) is considered to be divided in two main regions 
defined by the cutting point of the substrate peptide. The binding site part that 
recognises the C-terminus region of the peptide is called prime region (S’). The side at 
the N-terminus of the peptide is termed non-prime region (S). The two regions are 
mapped in sub-pockets starting from the cutting point towards the periphery of the 
substrate peptide. The S2’, S1, and S3 pockets were mainly involved in lipophilic 
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interactions. On the contrary, S1’, S2, S4 pockets were mainly involved in hydrophilic 
interactions 
 
Fig. 45.  BACE Binding Site Map. 
 
 
O O
OO
NH2NH2
HN+
NH
O
NH
O
NH
O
NH2NH2
HN+
NH3+
OH
NH2
O
NH3+
OH
NH2 NH2
HN+
S1
S3
S2
S1'
S2'
ASP32
ASP228
ARG235
S4
ARG307
LYS321
ASN233
SER325
GLN74
LYS107
PHE108
THR329
LYS224
ARG128
Cutting Point
Prime Region
Non-Prime Region
[S']
[S]
 
 
The main pockets of the BACE1 binding site are shown in this schema. For each pocket  hydrophilic 
interactions are also shown. In red:  the catalytic aminoacids Asp32 and Asp228 activate a water 
molecule that functions as the nucleophile responsible for amide cleavage 
 
 
Carbazole binding mode hypotheses  
With the aim of guiding the exploration of the carbazole class, two putative binding 
modes based on docking calculation were hypothesised. Docking studies were 
performed using the X-ray structure of BACE from the Protein Data Bank: 1FKN (Fig. 
46).60 
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Fig. 46.  3D Binding Site Map of BACE on 1FKN co-crystal structure   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due the high pseudo-symmetry of this class of molecules two opposite possible binding 
modes were found (a and b) (Fig. 47 and 48). 
 
Fig. 47. Carbazole binding mode a  
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Fig. 48. Carbazole binding mode b 
 
 
 
 
 
 
 
 
 
 
 
 
Carbazole group could occupy the subsites S1, S2, and S3 (fig. 47), but it could place 
itself also in S1’ and S2’ side (fig. 48). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inspired by screened compounds 6 and 7 two series of analogous molecules were 
designed (C and D) (Fig. 49). C and D series of carbazole derivatives were based on a 
common carbazolic structure and differs by the presence of a carboamidic moiety (C 
O O
OO
NH2 NH2
HN
N
S
O
OH
N O
S2
S1
S3
S1' ASP32
ASP228
ARG235
S2'
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series) or a sulfonamidic moiety (D series). In both series R’ may be an aryl or alkyl 
group such as phenyl, benzyl , phenylethyl, or cyclohexyl,  and R’’ is an hydrogen, 
halogen, methyl, or methoxy group.  
 
Fig. 49. C,D Series 
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Compound 6 and 7 also inspired two other series of analogous strucutures: indole 
derivatives (E series) and tetrahydrocarbazole derivatives (F series) (Fig. 50). We have 
synthesised a sulfonamidic structure where the carbazole group was substituted with an 
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indole and a tetrahydrocarbazole and where R’ may be an aryl or alkyl group such as 
benzyl, or phenylethyl, and R’’ is an hydrogen, halogen, methyl, or methoxy group. 
 
Fig. 50. E, F Series 
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 63
Screened compound 8 gave the idea for the last series of  β-naphtylaminic derivatives 
(Fig. 51) where we wanted to explore the activity of naphtylaminic compounds making 
modification around carbazolic moiety. 
Fig. 51. G Series 
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As concerns the synthesis of carbazole derivatives, some reaction conditions, already 
used at Siena Biotech laboratories, have been optimised for our series of compounds 
(Scheme 6).   
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Scheme 6.  C Series synthesis 
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The commercially available carbazole 35 was alkylated by a reaction with 
Epichlorohydrin in DMF and KOH as base. The reaction led to the desired epoxide 36 
with a 50% yield after crystallization from Et2O. This reaction could have two different 
type of mechanism: 1) SN2: epychloridrine may exchange a chloro atom with the 
carbazole nitrogen atom (Scheme 7); 2) Epoxide ring opening: the carbazole nitrogen 
atom may be alkylated by the primary oxirane carbon atom, then epoxide may re-form 
on the other side by elimination of chloridric acid (scheme 8). 
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Scheme 7. SN2 
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Scheme 8. Epoxide ring opening 
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The resulting epoxide was treated with different amines to obtain amino-alcol 37-40. 
After one night at 65°C, then we could generally see the product that precipitated in the 
reaction mixture as a white solid, and the yield ranged between 70 to 80%. Amino-alcol 
37-40 were treated with acyl-chlorides in the presence of PS-DIEA as base, and 
catalytic DMAP in CH2Cl2 and the reaction afforded compounds C1-9 with yields from 
30 to 75%. 
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Scheme 9.  D series synthesis 
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The D series synthesis (Fig. 9) started from amino alcol 37-40 prepared as in scheme 8. 
Amino alcol 37-40 were treated with sulfonyl-chlorides in the presence of PS-DIEA as 
base, and catalytic DMAP in CH2Cl2 and the reaction afforded compounds D1-14 with 
yields from 30 to 75%. 
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Synthesis for series E compounds is reported below (Scheme 10). 
 
Scheme 10.   E series synthesis 
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Commercially available indole 41 was alkylated by a reaction with epichlorohydrin in 
DMF and KOH as base. The reaction leaded to the desired epoxide 42 with a yield of 
50% after purification by flash cromtography. Epoxide 42 was treated with different 
amines to obtain the amino-alcol 43-46. Also in this case after one night at 65°C, we 
could generally see the product precipitated in the reaction mixture as a white solid and 
the yield ranged between 70 to 80%. Amino-alcol 43-46 were treated with sulfonyl 
chlorides in the presence of PS-DIEA as base, and catalytic DMAP in CH2Cl2 and the 
reaction afforded compounds E1-14 with yields from 30 to 75%. 
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Scheme 11.    F series synthesis 
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Commercially available 1,2,3,4-tetrahydrocarbazole 47 was alkylated by a reaction with 
epichlorohydrin in DMF and KOH as base. The reaction leaded to the desired epoxide 
48 with a 50% yield after purification by flash cromtography. Hence epoxide was 
treated with different amines to obtain the amino-alcol 49-50. Also in this case after one 
night at 65°C, we could generally see the product precipitated in the reaction mixture as 
a white solid and the yield ranged between 70 to 80%. Amino-alcol 49-50 was treated 
with sulfonyl-chlorides in the presence of PS-DIEA as base, and catalytic DMAP in 
CH2Cl2 and the reaction afforded compounds  F1-7 with yields from 30 to 75%. 
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G series synthesis 
β-Naphtylaminic derivatives can be collected with a general formula where R’’’ may be 
indole, 2,3-di-phenyl-indole, and tetrahydrocarbazole (Fig 52). Starting from different 
R’’’, the synthesis is general for all β-Naphtylaminic derivatives (Scheme 12). 
 
Fig. 52. β-Naphtylaminic derivatives 
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Scheme 12.   G series synthesis 
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The synthesis for this series (Scheme 12) started with the alkylation of commercial 
available compounds R’’’ by Epichlorohydrin. Compounds 42 and 48 have been 
prepared as in scheme 10 and 11 respectively. Alkylation of 2,3-di-phenyl indole 
afforded the desired product 51 which has been purified by crystallization with Et2O or 
by flash chromatography. Epoxides 42, 48, 51 were treated with  an excess of β-
naphtylamine in the presence of BiCl3 to encourage the opening of the epoxide with 
poorly nucleophilic amines such as β-naphtylamine . Final products G1-3 were purified 
by flash chromatography to remove unreacted starting material and excess of β-
naphtylamine. 
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RESULTS and DISCUSSION 
 
 
Series C, D, E, F and G compounds are shown in the following tables and IC50 μM of 
BACE inhibitory activity are reported. All synthesised compounds have been tested on 
BACE with a timeresolved fluorescence quenching assay.  
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Table 5.  C series 
N
OH
NR' O
R''
 
Compound R’ R’’ IC50 μM 
C1 4-Cl 4.7 
C2 4-OMe 3.8 
C3 
 
 
 2,4-Cl 2.5 
C4 H > 10 μM 
C5 4-Cl > 10 μM 
C6 2,4-Cl > 10 μM 
C7 
 
4-OMe > 10 μM 
C8 
 
 
 
 
H 4.8 
C9 
 
H > 10 μM 
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Table 6.  D Series 
N
OH
NR' S O
O
R''
 
Compound R’ R’’ IC50 μM 
6 
commercial 
compound 
H 3.0 
7 
commercial 
compound 
4-Me 2.6 
D1 4-Cl 2.9 
D2 
    
 
4-OMe 2.4 
D3 H 1.9 
D4 4-Me 2.7 
D5 4-Cl 1.7 
D6 
 
 
 
 4-OMe 1.6 
D7 H 2.8 
D8 4-Me 2.5 
D9 4-Cl 3.8 
D10 
 
 
 
 4-OMe 2.0 
D11 H 4.1 
D12 4-Me 3.9 
D13 
 
 
 4-Cl 6.5 
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D14  4-OMe 3.2 
 
Looking at the commercial compounds 6, 7 we have found that BACE inhibitory 
activity is preserved in both series C and D when R’ is a phenyl group. 
Activity has increased when R’ was a benzyl group in D. In C series the replacement of  
phenyl R’ with a benzyl group or a phenyl ethyl group led to a loss in activity on 
BACE. Differences in activity between carboamidic and sulfonamidic structures in this 
carbazolic series have been found: in general we had a loss in activity for carboamidic 
compounds (C series) when compared to sulfonyl series D. 
Generally, in both series C and D,  aromatic substituents in R’ are better tolerated than 
aliphatic groups (C2, D11-14). We had the best results in D series when R’ is a benzylic 
group. 
We have also noticed that among the D series with the same R’ group the activity 
increased when R’’ is a 4-methoxy group (D2>D1; D6>D3, D4, D5; D10>D7, D8, D9; 
D14>D11, D12, D13). 
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Table 7.    E series 
N
OH
NR' SO2
R''
 
 
Compounds R’ R’’ IC50 μM 
E1 H > 10 μM 
E2 
 
 
 
4-Me > 10 μM 
E3 H > 10 μM 
E4 4-Me > 10 μM 
E5 4-Cl > 10 μM 
E6 
 
 
 
 4-OMe > 10 μM 
E7 H 6.1 
E8 4-Me > 10 μM 
E9 4-Cl > 10 μM 
E10 
 
 
 
4-OMe > 10 μM 
E11 H > 10 μM 
E12 4-Me > 10 μM 
E13 
 
 
 
4-Cl > 10 μM 
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E14  4-OMe > 10 μM 
 
Replacing the carbazole with an indole portion we had a loss of activity, with the 
exception of compound E7 (R’= phenyl ethyl, R’’= hydrogen atom) which is able to 
inhibit BACE in the micromolar range (6.1 μM). Probably the carbazole group is 
needed for the interaction with BACE subsites as we assumed on the basis of 
computational studies previously reported. 
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Table 8.   F series 
 
N
OH
NR' SO2
R''
 
Compounds R’ R’’ IC50 μM 
F1 H 0.8 
F2 4-Me 1.7 
F3 4-Cl 1.2 
F4 
 
 
 
 
4-OMe > 10 μM 
F5 H 1.5 
F6 4-Me > 10 μM 
F7 
 
 
 4-Cl > 10 μM 
 
 
The best results were obtained with the tetrahydrocarbazole series (F series). As in 
carbazole series, also in this case, benzyl group was better tolerated than phenyl-ethyl 
group (R’). In particular, compound F1 (R’= benzyl, R’’= hydrogen atom) has shown 
the highest inhibitory activity on BACE (IC50 = 0.8 μM) among the compounds 
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developed in this thesis. Moreover, its IC50 value favourably compares with most 
previously reported BACE inhibitors. 
 
Table 9.   G Series 
 
Compound R’’’ IC50 μM 
8 
Commercial 
Compound 
 
N
OH
N
H
Br
Br
 
1.1 
G1 
N
OH
N
H  
> 10 μM 
G2 
N
OH
N
H  
> 10 μM 
G3 
N
OH
N
H  
> 10 μM 
 
 
The α-Naphtylamine G  series showed that when the 3,6-di-bromo carbazole moiety 
was replaced by an indole, a 2,3-di-phenyl indole, or a 1,2,3,4-tetrahydro carbazole, 
BACE inhibitory activity was found to be > 10 μM.  
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CONCLUSIONS 
 
On the basis of the modification made on carbazole screened structures, we found that 
BACE inhibitory activity was preserved in series C and D, which were mainly 
characterized by the carbazolic moiety. The activity was lost in E series when we 
replaced carbazole moiety with an indole; probably, the lack of one phenyl ring did not 
allow a good interaction between the molecules and the enzyme. This idea could be 
proved by the fact that in F series, characterized by a tetrahydrocarbazole moiety 
instead of carbazole, BACE inhibitory activity was still preserved and in some case it 
was also improved, like in compound F1 (IC50=0.8 μM). We can observe that in 
tetrahydrocarbazole, which has more lipophylic and less π features than fully aromatic 
carbazole, an extra aliphatic hydrophobic contribution was beneficial in terms of BACE 
inhibitory activity. 
 
Fig. 53.  Active compound F1 
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EXPERIMENTAL SECTION 
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GENERAL DETAILS 
 
Proton NMR spectra were recorded on a Bruker AC 200 (200 MHz) spectrometer as 
dilute solutions in deuterochloroform. The chemical shifts are recorded relative to 
tetramethylsilane as internal standard and the multiplicity of the signals is designated by 
one of the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; quin, 
quintet; br, broad; m, multiplet; with all various possible combinations (e.g. dd is double 
doublet). All coupling constants J, are reported in Hertz.  
Flash chromatography was performed on Merck silica gel 60 or on Isolute pre-packed 
silica columns and Isolute ionic exchanged pre-packed silica column as the stationary 
phase and the solvents employed were either of analytical grade or were distilled before 
the use.  
All reactions were monitored by TLC using Merck silica gel 60 F24 pre-coated 
aluminium backed plates which were visualised with ultraviolet light and/or basic 
potassium permanganate solution and phosphomolybdic acid. 
Dry organic solvents were stored under nitrogen and/or over sodium wire. The organic 
solvents were dried by distillation from the following: dichloromethane, pyridine, 
triethylamine, acetonitrile from calcium hydride; methanol from magnesium methoxide; 
benzene, toluene, THF and diethyl ether from sodium metal. N,N-dimethylformamide 
(DMF) Dimethylsulfoxide (DMSO) were purchased from Aldrich in SureSeal 
containers. 
All other commercially available reagents were used as received from Fluka, Sigma-
Aldrich, Merck, Lancaster. 
Solvents were removed by rotary evaporation in vacuo. 
Where necessary, reaction requiring anhydrous conditions were performed in a flame or 
oven-dried apparatus under a nitrogen atmosphere. 
All LCMS analyses were carried out using a Waters Alliance HT 2795 instrument with 
a Phenomenex C18 column and either a 5 or 10 minute gradient of acetonitrile/water 
containing 0.1% formic acid. 
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BIOLOGICAL ASSAY 
 
 
Biological assays have been preformed At Siena Biotech. A new homogeneous time-
resolved fluorescence quenching assay for the identification of BACE1 inhibitors have 
developed. A peptide with a fluorescent Eu-chelate coupled to the N-terminus as donor, 
and a quenching molecule at the C-terminus as acceptor, is used as substrate. Upon 
peptide cleavage by BACE1 the energy transfer between donor and acceptor is 
interrupted leading to increased fluorescence emission of the donor. Compound 
interference which is a common problem in FRET assays is minimized with this 
technology due to the large Stoke's shift and the time-resolved fluorescence emission of 
the Eu-chelate. A high signal-to-noise ratio of 13 and a Z' factor of 0.76 make this assay 
well suitable for HTS. 
Protease activity is often measured by monitoring the FRET process in peptide 
substrates coupled to donor-acceptor pairs undergoing hydrolysis. These assays offer 
the advantage of being sensitive and homogeneous but have also significant drawbacks 
including strong interference by organic compounds and a high background signal that 
often limits the substrate concentration to values well below the Km value. A good 
possibility for overcoming these problems is the use of TR-FRET technology which, 
based on the presence of lanthanide complexes (large Stoke’s shift and large 
fluorescence decay), allow time delayed detection of the emitted light. This provides the 
option of a temporal selection of signals, thus reducing compound interference. 
We developed a homogeneous time resolved fluorescence quenching assay for BACE1 
using a peptide substrate of 10 amino acids. The sequence contains the KM - NL APP  
Swedish mutation and has an Eu3+ chelate at the N-terminus (Ex max 330 nm- Em max 
615 nm) and a quenching organic fluorophore at the C-terminus. The proteolytic 
cleavage of the substrate produces a linear increase of fluorescence that is directly 
related to the enzyme activity and can be followed by kinetic TRF measurements. 
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Fig. 10 Principal of TR-FREET assay 
 
 
 
The assay was validated by reproducing the IC50 values of known and patented 
inhibitors and by determining the Ki value and binding mechanism of a known Stat-Val 
peptide inhibitor. All measured IC50 values correlated with published data.  
Ki for the Stat-Val peptide inhibitor was determined with various substrate 
concentrations (0.1-7 mM) and four different peptide concentrations (6, 15, 30 and 60 
nM). Data were plotted with the double reciprocal Lineweaver-Burk plot and Ki was 
graphically determined through a Cornish-Bowden plot.  
Reversibility and time dependency were established to better characterize the Stat-Val 
peptide inhibition. The reversibility was assessed through 10-times dilution of a mixture 
of 100 ng enzyme and compounds at 10-times the IC50 concentration after a pre-
incubation of 60 min at 25°C. The obtained activity was normalized to the control and 
compared to the activity of the concentrated mixture. 
This novel BACE1 assay is a robust and sensitive method suitable for HTS. The 
homogeneous and continuous nature of the assay makes it suitable for kinetic 
measurements. Problems with compound interference, frequently occurring with 
fluorescent FRET substrates, are not significant in this assay. The low background 
signal provides wide flexibility for substrate concentrations, thus allowing enzyme 
kinetics and Mode of Action studies. 
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SYNTHETIC PROCEDURES 
 
 
PATENTED COMPOUND (1) 
 
 
Compound (10)   
To a three neck flask under nitrogen with Mg (1.08g, 44.38 mmol) and I2 (cat) and Et2O 
(5 ml) a solution of bromobenzene (5.8g, 36.9 mmol) in Et2O (15 ml) was added 
dropwise. The mixture was refluxed for 0.5h. Then a solution of N-benzyl-piperidone 9 
(2g, 10.56 mmol) in Et2O (30 ml) was added dropwise. The mixture was refluxed for 1h 
and then left overnight at room temperature and then a saturated aqueous solution of 
NH4Cl was added dropwise to neutralise the unreacted Mg. The product was extracted 
with CHCl3 and the organic phase was evaporated in vacuo to give the desired product 
10 (3.38g) as a yellow oil (99% yield).  
1H NMR (200 MHz) CDCl3: δ 7.65-7.16 (m, 10H), 3.60 (s, 2H), 2.81 (dd, J= 2.2, 8.8 
Hz, 2H), 2.50 (td, J= 2.2, 12.0 Hz, 2H), 2.81 (td, J= 4.3, 13.0 Hz, 2H), 1.74 (dd, J= 2.5, 
14.1 Hz, 2H).  
 
Compound (11) 
Compound 10 (3.38g, 12.65 mmol) was treated with H2SO4 in CH3COOH sol 20% (50 
ml). The reaction mixture was stirred for 1h at room temperature and then NaOH 1N 
was added until pH 8 was reached. The desired product was extracted with Et2O and 
evaporated in vacuo. The crude was purified by flash chromatography (8:2 
Hexane/EtOAc) to give a yellow oil (11) (1.64g, 51.7% yield). 
1H NMR (200 MHz) CDCl3: δ 7.58-7.18 (m, 10H), 6.14-6.00 (m, 1H), 3.65 (s, 2H), 
3.18 (dd, J= 6.0, 2.7 Hz, 2H), 2.72 (t, J= 5.2 Hz, 2H), 2.61-2.47 (m, 2H). 
 
Compound (12) 
To a solution of olefin 11 (1.1g, 4.41 mmol) in THF (14 ml) BH3-DMS complex (4.4ml, 
8.8 mmol) was added dropwise and the reaction mixture was allowed to warm to reflux 
for 2h. After cooling to 0°C NaOH 1N (11 ml) was added dropwise and then H2O2 was 
added dropwise (16.5 ml). The reaction was allowed to warm to 100°C and stirred for 
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2h. After cooling to room temperature Et2O was added and the reaction mixture was 
washed with NaOH 1N, Na2S2O4 sat sol. and NH4Cl sat sol. The organic phase was 
collected and evaporated in vacuo and a yellow solid was obtained. Purification by flash 
chromatography (1:1 Hexane/EtOAc) afforded compound 12 as a white solid (800 mg, 
68% yield).  
1H NMR (200 MHz) CDCl3: δ 7.40-7.20 (m, 10H), 3.96-3.78 (m, 1H), 3.60 (AB q, J= 
15.9, 13.1 Hz, 2H), 3.27-3.15 (m, 1H), 3.20-2.88 (m, 1H), 2.50-2.31 (m, 1H), 2.17-1.75 
(m, 4H), 1.63-1.48 (m, 2H). 
 
Compound (13)  
Compound 12 (520 mg, 1.94 mmol) was dissolved in CH3CN and biphenyl carbonyl 
chloride (2.1g, 9.7 mmol), Et3N (2.1 ml, 15.52 mmol), DMAP (cat) were added. The 
mixture was stirred overnight at room temperature, then it was quenched with H2O and 
NH4OH sol 30% and extracted with EtOAc. The organic phase was washed with 
NaHCO3 sol sat and evaporated in vacuo. Purification by flash chromatography (7:3 
Hexane/EtOAc) afforded 798 mg (92% yield) of desired product 13 as a yellow solid. 
1H NMR (200 MHz) CDCl3: δ 7.88 (AA’XX’, J= 8.4, 4.0 Hz, 2H), 7.64-7.51 (m, 4H), 
7.51-7.09 (m, 12H), 5.39 (td, J= 10.3, 4.6 Hz, 1H), 3.64 (dd, J= 21.4, 13.1 Hz, 2H), 
3.48-3.55 (m, 1H), 3.04-2.93 (m, 1H), 2.93-2.75 (m, 1H), 2.26-1.84 ( m, 4H). 
 
Compound (1) 
Compound 13 (200mg, 0.45 mmol) was dissolved in EtOAc (23 ml) and Pd /C 10% 
(281.1 mg, 0.60 mmol) was added. The reaction mixture was stirred under H2 for 15 
days and then filtered on Celite and washed with EtOAc. The organic phase was 
evaporated and purification by flash chromatography (9:1 Hexane/EtOAc) afforded the 
desired product 1 (149 mg) as a white solid (80% yield). 
1H NMR (200 MHz) CDCl3: δ 7.8 (AA’XX’, J= 8.4, 4.0 Hz, 2H), 7.64-7.50 (m, 4H), 
7.50-7.12 (m, 8H), 5.18 (td, J= 10.3, 4.5 Hz, 1H), 3.50 (dd, J= 11.7, 4.5 Hz, 1H), 3.17 
(d, J= 12.4 Hz, 1H), 2.97 (td, J= 11.3, 3.8 Hz, 1H), 2.87-2.60 (m, 2H), 2.10-1.70 (m, 
2H). 
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PATENTED COMPOUND (4) 
 
Compound (15) 
Commercially available N-boc-lysine 14 (2g, 8.1 mmol) was dissolved in NaOH 2N (6 
ml) and cooled to 0°C. Benzyl-chloroformate (1.26 ml, 8.9 mmol), and NaOH 2N (2.6 
ml) were added dropwise. The mixture was stirred 1h at 0°C and 1h at room 
temperature then was washed with Et2O. HCl 2N was added to the inorganic phase until 
acid pH and extracted with EtOAc. The organic phase was evaporated and an oil (15) 
was obtained which was used as crude for the next reaction. 
1H NMR (200 MHz) CDCl3: δ 7.39-7.28 (m, 5H), 5.33-4.90 (m, 3H), 4.40-4.18 (m, 
1H), 3.18 (dd, J= 12.2, 6.2 Hz, 2H), 1.98-1.10 (m, 6H), 1.43 (s, 9H). 
 
Compound (16)  
N-Boc-N-cbz-lysine 15 (2.17g, 5.7 mmol) was dissolved in DMF (20 ml) under 
nitrogen and K2CO3 was added. The heterogeneous mixture was stirred 1h at room 
temperature then Benzyl-bromide (0.35 ml, 3.13 mmol) was added dropwise. The 
reaction was stirred for 3h at room temperature and then HCl 2N was added until pH 
was adjusted to 3 and extracted with EtOAc. Purification by flash chromatography 
afforded the desired product 16 (1.28g) as a yellow oil (87% yield). 
1H NMR (200 MHz) CDCl3: δ 7.42-7.28 (m, 10H), 5.30-4.98 (m, 5H), 4.88-4.65 (m, 
1H), 4.44-4.22 (m, 1H), 3.13 (dd, J= 12.5, 6.2 Hz, 2H), 1.90-1.20 (m, 6H), 1.42 (s, 9H). 
 
Compound (17)  
Compound 16 ( 690 mg, 1.46mmol) was added to a solution of CH2Cl2 (7.9 ml) and 
TFA under nitrogen (2.6 ml) and was stirred for 2h at room temperature. Then CH2Cl2 
was evaporated and K2CO3 was added. The desired product 17 was extracted with 
EtOAc and obtained as an oil (625 mg). 
1H NMR (200 MHz) CDCl3: δ 7.44-7.28 (m, 10H), 5.14 (s, 2H), 5.08 (s, 2H), 3.54-3.38 
(m, 1H), 3.15 (dd, J= 12.8, 6.4 Hz, 2H), 1.88-1.19 (m, 6H). 
 
Compound (18) 
Compound 17 (625mg, 1.68mmol) was dissolved in MeOH (20 ml) and CH3COOH 
glac. (0.23 ml, 4.2 mmol), NaBH3CN( 126.6 mg, 2.01 mmol) were added. The mixture 
was cooled to 0°C and then a solution of isobutyraldheyde (0.18 ml, 2.01 mmol) in 
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MeOH (8 ml) was added dropwise. After 1h at room temperature MeOH was 
evaporated and K2CO3 was added until basic pH. The product was extracted with 
EtOAc and an oil was obtained (18)(687 mg). 
1H NMR (200 MHz) CDCl3: δ 7.48-7.24 (m, 10H), 5.15 (d, J= 4.4 Hz, 2H), 5.08 (s, 
2H), 4.84-4.66 (m, 1H), 3.30-3.00 (m, 3H), 2.33 (dd, J= 10.0, 7.2 Hz, 1H), 2.23 (dd, J= 
11.1, 6.2 Hz, 1H), 1.80-1.20 (m, 7H), 0.98-0.73 (m, 6H). 
 
Compound (19) 
Compound 18 (687 mg, 1.61 mmol) was dissolved in CH2Cl2 ( 3 ml) and p-nitro-
benzensulfonyl-chloride (535.2 mg, 2.41 mmol) and DIEA (0.28 ml, 1.77 mmol) were 
added. The reaction mixture was stirred overnight at room temperature, quenched with 
HCl 1N and extracted with EtOAc. Purification by flash chromatography (7:3 
Hexane/EtOAc) afforded the desired product 19 (227 mg) as a yellow oil (23% yield). 
1H NMR (200 MHz) CDCl3: δ 8.03 (AA’XX’, J= 8.9, 4.3 Hz, 2H), 7.85 (AA’XX’, J= 
8.9, 4.3 Hz, 2H), 7.44-7.28 ( m, 8H), 7.22-7.08 (m, 2H), 5.10 (s, 2H), 4.89 (s, 2H), 4.50 
(dd, J= 8.2, 6.5 Hz, 1H), 3.20 (dd, J= 12.7, 6.5 Hz, 2H), 3.03 (dd, J= 14.6, 7.8 Hz, 1H), 
2.86 (dd, J= 14.6, 7.1 Hz, 1H), 2.20-1.15 (m, 7H), 1.00-0.60 (m, 6H). 
 
Compound (21) 
Compound 19 (297 mg, 0.48 mmol) was dissolved in EtOAc and Pd/C 10% (0.4 eq) 
was added. The mixture was stirred under H2 for 4 days at room temperature. Then the 
heterogeneous phase was filtered on Celite and the solution was evaporated to give the 
desired product 21 (112 mg) (65% yield). 
 
Compound (4) 
To a solution of K2CO3 1M/THF/CH3CN (1:1:1) (2 ml) compound 21 (112 mg, 0.31 
mmol) and Fmoc-succinimide (116 mg, 0.34 mmol) were added and the mixture was 
stirred for 2h at room temperature. HCl 1N was added unitl pH was adjust to acidity and 
the product was extracted with EtOAc. Purification by flash chromatography afforded 
pure compound 1 as a white solid (77 mg, 42% yield). 
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3-AMINOPIPERIDINE DERIVATIVES 
 
A SERIES 
 
Compounds (23-26) 
General procedure. To a solution of commercial N-Boc-3-amino-piperidine 22 (1 
mmol) in DCM (5 ml), aldehyde (1.2 mmol), Sodium cyanoborohydride (1.2 mmol) and 
acetic acid (2.5 mmol) were added. The reaction mixture was stirred at room 
temperature for 3 h and then was quenched with K2CO3 1M and extracted with DCM. 
The organic phase was separated and evaporated in vacuo. The products were purified 
by SCX silica column. 
  
Compound (23)  
Purified by scx silica column (90% yield);  
1H NMR (200 MHz) CDCl3: δ 7.34-7.24 (m, 5H), 3.92-3.70 (m, 3H), 2.97-2.59 (m, 
3H), 1.94-1.31 (m, 5H), 1.43 (s, 9H). 
 
Compound (24)  
Purified by scx silica column (95% yield);  
1H NMR (200 MHz) CDCl3: δ 7.62-7.48 (m, 4H), 7.48-7.27 (m, 5H), 3.96.3.69 (m, 
3H), 3.00-2.45 (m, 3H), 1.46 (s, 9H), 1.97-1.35 (m, 5H). 
 
Compound (25)  
Purified by scx silica column (44% yield));  
1H NMR (200 MHz) CDCl3: δ 7.48- 7.32 (m, 9H), 3.87-3.67 (m, 3H), 2.88-2.73 (m, 
1H), 2.73-2.47 (m, 1H), 2.47-2.35 (m, 1H), 1.42 (s, 9H), 1.75-1.12 (m, 5H). 
 
Compound (26)  
Purified by scx silica column (90% yield);  
1H NMR (200 MHz) CDCl3: δ 7.63-7.27 (m, 9H), 3.98-3.69 (m, 3H), 2.99-2.63 (m, 
3H), 1.95-1.87 (m, 1H), 1.47 (s, 9H), 1.76-1.28 (m, 4H). 
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Compounds (A1-A7) 
General procedure. Secondary amines 23-26 (1 mmol) was dissolved in DCM then 
Acyl chlorides (1.1 mmol), PS-DIEA (1.5 mmol) and DMAP cat. were added. After 
stirring overnight at room temperature the reaction mixture was filtered and evaporated 
in vacuo. The products were purified by flash chromatography. 
 
Compound (A1) 
Purified by flash chromatography (90% Hexane/EtOAc - CH2Cl2) (70% yield);  
1H NMR (200 MHz) CDCl3: δ 7.70-7.15 (m, 14H), 4.70-4.45 (m, 2H), 4.30-3.60 (m, 
3H), 1.39 (s, 9H), 2.00-1.20 (m, 4H). 
 
Compound (A2)  
Purified by flash chromatography (90 to 85% Hexane/EtOAc) (60% yield);  
1H NMR (200 MHz) CDCl3: δ 7.70-7.19 (m, 14 H), 5.07-4.32 (m, 2H), 4.31-3.58 (m, 
3H), 2.95-2.61 (m, 1H), 2.60-2.26 (m, 1H), 1.98-1.76 (m, 1H), 1.75-1.07 (m, 3H), 1.38 
(s, 9H). 
 
Compound (A3)  
Purified by flash chromatography (90 to 80% Hexane/EtOAc) (85% yield);  
1H NMR (200 MHz) CDCl3: δ 7.70-7.52 (m, 11H), 7.51-7.27 (m, 7H), 5.00-4.42 (m, 
2H), 4.40-3.70 (m, 3H), 3.00-2.35 (m, 1H), 2.03-0.91 (m, 1H), 1.39 (s, 9H), 1.78-0.90 
(m, 4H). 
 
Compound (A4) 
Purified by flash chromatography (90 to 80% Hexane/EtOAc) (75% yield); 
1H NMR (200 MHz) CDCl3: δ 7.65-7.10 (m, 12H), 5.20-4.50 (m, 2H), 4.30-3.70 (m, 
2H), 3.18-2.68 (m, 1H), 2.69-2.38 (m, 2H), 1.36 (s, 9H), 1.95-1.22 (m, 4H). 
 
 
Compound (A5)  
Purified by flash chromatography (90 to 80% Hexane/EtOAc) (28% yield);  
 90
1H NMR (200 MHz) CDCl3: δ 7.63-7.27 (m, 11H), 7.18-7.02 (m, 2H), 4.90-4.40 (m, 
2H), 4.26-3.89 (m, 2H), 3.89-3.69 (m, 1H), 3.18-2.68 (m, 1H), 2.67-2.38 (m, 1H), 1.37 
(s, 9H), 1.95-1.22 (m, 4H). 
 
Compound (A6)  
Purified by flash chromatography (90 to 80% Hexane/EtOAc) (75% yield);  
1H NMR (200 MHz) CDCl3: δ 7.67-7.19 (m, 14H), 5.00-4.22 (m, 2H), 4.20-3.40 (m, 
3H), 2.61-2.01 (m, 2H), 1.36 (s, 9H), 1.68-0.88 (m, 4H). 
 
Compound (A7)  
Purified by flash chromatography (90% Hexane/EtOAc) (60% yield);  
1H NMR (200 MHz) CDCl3: δ 7.70-7.20 (m, 14H), 5.10-4.40 (m, 2H), 4.39-3.60 (m, 
3H), 3.10-2.64 (m, 1H), 2.30-2.63 (m, 1H), 1.37 (s, 9H), 2.00-0.98 (m, 4H). 
 
 
Compounds (A8-A9) 
General procedure. Boc-compound (1 mmol) was dissolved in a solution of 
TFA/DCM (4 ml) and stirred for 2 hours at room temperature. The products were 
collected after concentration under vacuum and purified with flash chromatography. 
 
Compound (A8)  
Purified by crystallization with Hexane/Et2O (57% yield);  
1H NMR (200 MHz) CDCl3: δ 7.70-7.15 (m, 14H), 5.00-4.40 (m, 2H), 4.20-3.70 (m, 
1H), 3.50-2.27 (m, 4H), 1.99-1.15 (m, 4H). 
 
Compound (A9)  
Purified by flash chromatography (70% Hexane/EtOAc- 90% CHCl3/MeOH ) (90% 
yield);  
1H NMR (200 MHz) CDCl3: δ 7.67-7.50 (m, 4H), 7.50-7.20 (m, 10H), 5.00-4.35 (m, 
2H), 4.35-3.50 (m, 1H), 3.30-2.18 (m, 3H), 2.05-1.10 (m, 5H). 
 
Compound (A10) 
To a solution of amine (1 mmol) in DCM, phenyl-acetyl-chloride (1.1 mmol), PS-DIEA 
(1.5 mmol) and DMAP cat. was added. The mixture was stirred at room temperature 
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overnight, then the desired product A10 was recovered by filtration and evaporation 
under vacuum, and purified by flash chromatography (80% Hexane/EtOAc) (70% 
yield). 
1H NMR (200 MHz) CDCl3: δ 7.70-7.04 (m, 19H), 4.78-4.35 (m, 4H), 3.80-3.50 (m, 
3H), 2.89-2.60 (m, 1H), 2.50-2.25 (m, 1H), 2.00-1.60 (m, 4H). 
 
 
B SERIES 
 
Compounds (23-26)  
Prepared as previously described for A series. 
 
Compounds (B1-B7) 
General procedure. Secondary amines 23-26 (1 mmol) was dissolved in DCM then 
sulfonyl-chloride (1.1 mmol), PS-DIEA (1.5 mmol) and DMAP cat. were added. After 
stirring overnight at room temperature the reaction mixture was filtered and evaporated 
in vacuo. The products were purified by flash chromatography. 
 
Compound (B1)  
Purified by flash chromatography (CH2Cl2) (32% yield);  
1H NMR (200 MHz) CDCl3: δ 7.89 (AA’XX’, J= 8.4, 2.0 Hz, 2H), 7.70 (AA’XX’, J= 
8.6, 1.5 Hz, 2H), 7.65-7.24 (m, 10H), 4.45 (AB quartet, J= 15.8 Hz, 2H), 3.90-3.85 (m, 
2H), 3.85-3.60 (m, 1H), 2.51 (t, J= 11.7 Hz, 1H), 2.45-2.20 (m, 1H), 1.40 (s, 9H), 1.54-
1.25 (m, 4H). 
 
Compound (B2)  
Purified by flash chromatography (90% Hexane/EtOAc) (38% yield);  
1H NMR (200 MHz) CDCl3: δ 7.92-7.80 (m, 2H), 7.69-7.27 (m, 12H), 4.46 (AB 
quartet, J= 16.0 Hz, 2H), 4.10-3.83 (m, 1H), 3.82-3.55 (m, 1H), 2.55 (t, J= 23.8 Hz, 
1H), 2.93-2.20 (m, 1H), 1.40 (s, 9H), 1.80-1.08 (m, 4H). 
 
Compound (B3)  
Purified by flash chromatography (100 to 90% Hexane/EtOAc) (53% yield);  
1H NMR (200 MHz) CDCl3: δ 7.9 (AA’XX’, J= 8.4, 2.0 Hz, 2H), 7.70 (AA’XX’, J= 
8.4, 2.0 Hz, 2H), 7.65-7.27 (m, 14H), 4.49 (AB quartet, J= 16.0 Hz, 2H), 4.20-3.90 (m, 
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1H), 3.89-3.67 (m, 1H), 2.59 (t, J= 12.0 Hz, 1H), 2.50-2.26 (m, 1H), 1.40 (s, 9H), 1.85-
1.08 (m, 4H). 
 
 
 
Compound (B4)  
Purified by flash chromatography (100 to 90% Hexane/EtOAc) (35% yield);  
1H NMR (200 MHz) CDCl3: δ 7.85 (d, J= 8.6 Hz, 1H), 7.63-7.15 (m, 10), 4.57 (AB 
quartet, J= 16.0 Hz, 2H), 4.20-3.96 (m, 2H), 3.88-3.61 (m, 1H), 2.60 (t, J= 11.8 Hz, 
1H), 2.40 (bt, J= 12.0 Hz, 1H), 1.94-1.87 (m, 1H), 1.41 (s, 9H), 1.73-1.22 (m, 3H). 
 
Compound (B5)  
Purified by flash chromatography (80% Hexane/EtOAc) (55% yield);  
1H NMR (200 MHz) CDCl3: δ 7.89-7.80 (m, 2H), 7.62-7.11 (m, 11H), 4.43 (AB 
quartet, J= 16.0 Hz, 2H), 2.56 (t, J= 11.8 Hz, 1H), 3.27-2.49 (m, 1H), 1.40 (s, 9H), 
1.80-1.22 (m, 4H). 
 
Compound (B6)  
Purified by flash chromatography (90% Hexane/EtOAc) (24% yield);  
1H NMR (200 MHz) CDCl3: δ 7.87-7.68 (m, 3H), 7.65-7.16 (m, 11H), 4.39 (AB 
quartet, J= 16.5 Hz, 2H), 4.00-3.65 (m, 2H), 3.65-3.34 (m, 1H), 2.40-2.10 (m, 2H), 1.38 
(s, 9H), 1.52-0.88 (m, 4H). 
 
Compound (B7)  
Purified by flash chromatography (80% Hexane/EtOAc) (61% yield);  
1H NMR (200 MHz) CDCl3: δ 7.92-7.80 (m, 2H), 7.65-7.27 (m, 12H), 4.49 (AB 
quartet, J= 16.3 Hz, 2H), 4.12-3.86 (m, 2H), 3.85-3.61 (m, 1H), 2.55 (t, J= 11.8 Hz, 
1H), 2.45-2.21 (m, 1H), 1.39 (s, 9H), 1.80-1.20 (m, 4H). 
 
 
Compound (B8) 
 Boc-compound B5 (1 mmol) was dissolved in a solution of TFA/DCM (4 ml) and 
stirred for 2 hours at room temperature. The product was collected after concentration 
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under vacuum. Purification by crystallization with Hexane/Et2O afforded pure product 
B8 (52% yield).  
1H NMR (200 MHz) CDCl3: δ 7.90 (AA’XX’, J= 8.6, 2.0 Hz, 2H), 7.71 (AA’XX’, J= 
8.6, 2.0 Hz, 2H), 7.68-7.57 (m, 2H), 7.57-7.20 (m, 8H), 4.46 (AB quartet, J= 16.0 Hz, 
2H), 4.00-3.65 (m, 1H), 3.05-2.86 (m, 1H), 2.49-1.82 (m, 3H), 1.80-1.00 (m, 4H). 
 
Compound (B9) 
To a solution of amine B8 (1 mmol) in DCM, phenyl-acetyl-chloride (1.1 mmol), PS-
DIEA (1.5 mmol) and DMAP cat. was added. The mixture was stirred at room 
temperature overnight, then the desired product B9 was recovered by filtration and 
evaporation under vacuum, and purified by flash chromatography (80% Hexane/EtOAc) 
(61% yield). 
1H NMR (200 MHz) CDCl3: δ 8.00-7.10 (m, 19H), 4.72-4.20 (m, 4H), 3.87-3.68 (m, 
2H), 2.70-2.38 (m, 2H), 2.30-2.05 (m, 1H), 1.67-0.95 (m, 4H). 
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ANALOGUE OF TETRALINE DERIVATIVES 
 
 
Compound (29) 
Commercially available 4-benzyloxy-2-hydroxy-benzaldehyde 28 (2g, 8.7 mmol, 1 eq) 
was treated with epichlorohydrin (2.10 ml, 3 eq) and 7-8 drops of piperidine were 
added. The reaction mixture was stirred 4 hours at 100°C in a closed vial. After 
complete reaction CHCl3 was added and conc HCl to open the unreacted epoxide. The 
organic phase was separated and washed with water, then evaporated in vacuo. The 
desired product 29 was purified with Flash Chromatography (90 to 80 Hexane/ EtOAc) 
(52% Yield).  
1H NMR (200 MHz) CDCl3: δ 10.19 (s, 1H), 7.77 (d, J= 8.7 Hz, 1H), 7.50-7.26 (m, 
4H), 6.68 (dd, J= 8.6, 2.0 Hz, 1H), 6.56 (d, J= 2.1 Hz, 1H), 5.34 (s, 2H), 4.40-4.00 (m, 
3H), 3.77 (dd, J= 5.2, 1.3 Hz, 2H), 2.99 (d, J= 5.8 Hz, 1H). 
 
Compound (30) 
Aldehyde 29 (1.45 g, 1 eq) was dissolved in MeOH, then H2O2 sol. 35% (0.5 ml, 1.3 eq) 
and KHSO4 (96 mg, cat) were added. After 1 night at room temperature the mixture was 
diluited with H2O and extracted with CHCl3. Compound 30 was obtained and used as a 
without further purification for the next reaction. 
 
Compound (31) 
Phenol 30 (1.3 g) was treated with an excess of 2N KOH. The mixture was allowed to 
react 1 hour at room temperature and a oil appeared in the mixture. The desired product 
was extracted with CH2Cl2 and purified by flash chromatography (8:2 Hexane EtOAc). 
A yellow oil 31 was obtained with a yield of 81%.  
1H NMR (200 MHz) CDCl3: δ 7.50-7.25 (m, 4H), 6.80 (d, J= 8.4 Hz, 1H), 6.60-6.40 
(m, 2H), 4.98 (s, 2H), 4.40-3.88 (m, 3H), 3.88-3.70 (m, 2H). 
 
Compound (32) 
1,4-benzodioxane 31 (887 mg, 1 eq) was dissolved in EtOH (15ml) and EtOAc (6-7 
drops). Pd/C 10% was added and the mixture was allowed to react under H2 for 5 hours. 
The mixture was filtered on Celite and the solution was evaporated in vacuo. 
Compound 32 was obtained with 92% yield.  
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1H NMR (200 MHz) CDCl3: δ 6.75 (d, J= 8.6 Hz, 1H), 6.44-6.28 (m, 2H), 4.35-3.60 
(m, 5H). 
 
Compound (33) 
Phenol 32 (563 mg, 1 eq) was dissolved in CH3CN (5 ml), then K2CO3 (767.7 mg, 1.8 
eq) was added and the mixture was allowed to warm to 60°C. A solution of phenyl-
benzyl-chloride (688.8 mg, 1.1 eq) in CH3CN (1 ml) was added. Subsequently catalytic 
KI (a spatula tip) was added. After the mixture was stirred at 80°C for 1 night CH3CN 
was evaporated. The crude was acidified with HCl 4N and extracted with CHCl3. 
Desired product 33 was purified by flash chromatography (90 to 80% Hexane/EtOAc) 
with 90% yield.  
1H NMR (200 MHz) CDCl3: δ 7.70-7.25 (m, 8H), 6.82 (d, J= 8.6 Hz, 1H), 6.62-6.43 
(m, 2H), 5.02 (s, 2H), 4.40-3.98 (m, 3H), 3.98-3.70 (m, 2H). 
 
Compound (34) 
To a solution of PhP3 ( 88.1 mg, 1.2 eq) in THF (1.5 ml) imidazole (21.8 mg, 1.15 eq) 
and I2 (85.2 mg, 1.2 eq) were added. Then a solution of alcohol 33 (200 mg, 1 eq) in 
THF (1.5 ml) was added. After 5 hours at room temperature the mixture was treated 
with Na2S2O4 sol sat was added and desired product 34 was extracted with CH2Cl2.  
 
Compound (5) 
To a solution of compound 34 (eq 1) dimethylamine (3 ml, 8 eq) in THF (1 ml) K2CO3 
(196.65 mg, 2.5 eq) was added and then a solution of iodide ( 250 mg, 1 eq) in THF (2.5 
ml) was added. The mixture was stirred at room temperature for 3 days. Then the 
mixture was washed with H2O and extracted with CH2CL2. Purification by flash 
chromatography (80 to 50% Hexane/EtOAc) afforded the final product 5 as a white 
solid which has been treated with HCl to form the hydrochloride salt. A white solid (39 
mg) has been obtained with a yield of 17% (5·HCl).  
1H NMR (200 MHz) CDCl3: δ 7.80-7.26 (m, 8H), 6.83 (d, J= 8.4 Hz, 1H), 6.60-6.46 
(m, 2H), 5.01 (s, 2H), 4.36-4.14 (m, 2H), 4.04-3.86 (m, 1H), 2.70-2.40 (m, 2H), 2.32 (s, 
6H). 
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CARBAZOLE DERIVATIVES 
 
C SERIES 
 
Compound (36) 
Carbazole 35 (5g, 1 eq) was dissolved in DMF (70 ml) and KOH (1.2 eq) was added 
and cooled to 0°C. Then a solution of Epichlolohydrin (2.5 eq) in DMF (20 Ml) was 
added dropwise. After stirring at 0°C for 5 h the mixture reaction was quenched with 
water and ice and extracted with EtOAc. The organic phase was separated and 
evaporated in vacuo, and a yellow oil was obtained. Crystallization by Et2O afforded 
pure compound 36 (50% yield);  
1H NMR (200 MHz) CDCl3: δ 8.12-8.08 (m, 2H), 7.55-7.40 (m, 4H), 7.33-7.22 (m, 
2H), 4.64 (dd, J=15.7, 3.2 Hz, 1H), 4.40 (dd, J=15.7, 4.7 Hz, 1H), 3.39-3.21 (m, 1H), 
2.81 (ψ t, J= 4.2, 1H), 2.57 (dd, J= 4.7, 2.5 Hz, 1H). 
 
 
Compounds (37-40) 
General procedure. Epoxide 36 ( 1 g, 1 eq) was dissolved in EtOH (10 ml), and 
amines (2 eq) were added. The reaction mixture was stirred at 65°C overnight. After 
complete reaction EtOH was evaporated in vacuo. 
Compound (37) 
Purified by crystallization with Et2O (yield 40%);  
1H NMR (200 MHz, CDCl3) δ 2.17-2.15 (m, 1H), 3.44-3.22 (m,2H), 4.47 (s, 2H), 6.78-
6.61 (m, 3H),7.29-7.14 (m, 4H), 7.48-7.44 (m, 4H), 8.11 (d, 2H, J=7.69Hz); 
 
 
Compound (38)  
Purified by crystallization with Et2O (75% yield);  
1H NMR (200 MHz) CDCl3: δ 8.0 (d, J= 7.6 Hz, 2H), 7.50-7.41 (m, 4H), 7.36-7.20 (m, 
7H), 4.40-4.37 (m, 2H), 4.25-4.16 (m, 1H), 3.72 (d, J= 3.2 Hz, 2H), 2.82 (dd, J= 12.0, 
3.6 Hz, 1H), 2.66 (dd, J= 12.1, 8.1 Hz, 1H). 
 
Compound (39) 
Purified by flash chromatography (95 to 70% Hexane/EtOAc) (70% yield);  
 97
1H NMR (200 MHz) CDCl3: δ 8.0 (d, J= 7.6 Hz, 2H), 7.50-7.36 (m, 3H), 7.32-7.18 (m, 
8H), 4.40-4.27 (m, 2H), 4.20-4.09 (m, 1H), 2.86-2.53 (m, 5H), 2.11 (bs, 2H). 
 
Compound (40)  
Purified by crystallization with Et2O (79% yield);  
1H NMR (200 MHz) CDCl3: δ 8.09 (d, J= 7.6 Hz, 2H), 7.51-7.41 (m, 3H), 7.30-7.19 
(m, 2H), 4.38-4.30 (m, 2H), 4.16-4.04 (m, 1H), 2.58 (dd, J= 12.0, 8.6 Hz, 1H), 2.32 (tt, 
J= 10.1, 7.04 Hz, 1H), 1.87-1.52 (m, 5H), 1.29-0.87 (m, 5H). 
 
 
Compounds (C1-C9) 
General procedure. To a solution of amine (200mg, 1 eq) in CH2Cl2 (4 ml) Aryl-
chloride (1.1 eq), PS-DIEA (1.2 eq) and DMAP (cat.) was added. The reaction mixture 
was stirred overnight at room temperature and then filtered and evaporated in vacuo. 
The products were purified by flash chromatography. 
 
Compound (C1)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (yield 57%); 1H NMR 
(200 MHz, CDCl3) δ 3.64-3.61 (m, 1H), 3.92-3.88 (m, 1H), 4.39-4.23 (m, 2H), 4.48-
4.47 (m, 1H), 6.90-6.86 (m, 2H), 7.11-7.08 (m, 4 H), 7.24 -7.17 (m, 4 H), 7.43-7.41 (m, 
4H), 8.05 (d, 2H, J=7.69 Hz). 
 
Compound (C2)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (yield 57%); 1H NMR 
(200 MHz, CDCl3) δ 3.70 (s, 3H), 3.88-3.84 (m, 1H), 4.11-4.05 (m, 3H), 4.46-4.39 (m, 
3H), 6.63-6.54 (m, 2H), 6.90-6.87 (m, 2H), 7.09-7.05 (m, 3H), 7.24 -7.22 (m, 4 H), 
7.41-7.39 (m, 4H), 8.04 (d, 2H, J=7.69 Hz). 
 
Compound (C3)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (yield 40 %); 1H NMR 
(200 MHz, CDCl3) δ 3.43-3.41 (m, 1H), 3.92-3.88 (m, 1H), 4.18-4.09 (m, 1H), 4.38-
4.35 (m, 2H), 4.48-4.43 (m, 1H), 6.97-6.90 (m, 3H), 7.14-7.12 (m, 4H), 7.25 -7.21 (m, 2 
H), 7.47-7.39 (m, 5H), 8.05 (d, 2H, J=7.69 Hz). 
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Compound (C4)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (yield 90%); 1H NMR 
(200 MHz, CDCl3) δ 3.28 (d, 1H, J=14.50 Hz), 4.29-3.86 (m, 1H), 4.40-4.26 (m, 5H) 
6.76-6.64 (m, 2H), 7.10-6.94 (m, 2H), 7.46-7.20 (m, 12 H), 8.08 (d, 2H, J=7.69 Hz); 
 
Compound (C5)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (48% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.08 (d, J= 7.5 Hz, 2H), 7.46-7.00 (m, 13H), 6.80-6.65 (m, 2H), 
4.45-4.13 (m, 5H), 3.94-3.86 (m, 1H), 3.30 (d, J= 13.9 Hz, 1H). 
 
Compound (C6)  
Purified by flash chromatography (90 to 85% Hexane/EtOAc) (74% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.08 (d, J= 7.6 Hz, 2H), 7.52-7.10 (m, 12H), 6.80-6.60 (m, 2H), 
4.30-3.83 (m, 6H), 3.36 (d, J= 13.7 Hz, 1H). 
 
Compound (C7)  
Purified by flash chromatography (90 to 70% Hexane/EtOAc) (30% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.07 (d, J= 7.6 Hz, 2H), 7.45-7.19 (m, 7H), 7.10-6.90 (m, 3H), 
6.87-6.73 (m, 5H), 4.40-4.13 (m, 5H), 4.05-3.80 (m, 1H), 3.80 (s, 3H), 3,25 (d, J= 13.9 
Hz, 1H). 
 
 
Compound (C8)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (57% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.10 (d, J= 7.6 Hz, 2H), 7.54-7.45 (m, 4H), 7.44-7.07 (m, 11H), 
6.51-6.43 (m, 2H), 4.56-4.45 (m, 4H), 4.10-3.95 (m, 3H), 2.30-2.25 (m, 2H). 
 
 
Compound (C9)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (11% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.1 (d, J= 7.6 Hz, 2H), 7.60-7.35 (m, 3H), 7.37-7.21 (m, 8H), 
4.55-4.23 (m, 3H), 3.80-3.69 (m, 1H), 3.17-3.05 (m, 2H), 1.52-0.44 (m, 10H). 
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D SERIES 
 
 
Compounds (37-40)  
Prepared as previously described for C series. 
 
 
Compounds (D1-D14) 
General procedure. To a solution of amine (200mg, 1 eq) in CH2CL2 (4 ml) Aryl-
sulfonyl chloride (1.1 eq), PS-DIEA (1.2 eq) and DMAP (cat.) was added. The reaction 
mixture was stirred overnight at room temperature and then filtered and evaporated in 
vacuo. The products were purified by flash chromatography. 
 
Compound (D1)  
Yield 66 %; 1H NMR (200 MHz, CDCl3) δ 2.22 (s, 1H), 3.71-3.69 (m, 2H), 4.30-4.23 
(m, 2H), 4.54-4.51 (m, 1H), 7.35-7.08 (m, 2H), 7.24-7.19 (m, 2H), 7.35-7.31 (m, 5H), 
7.42-7.38 (m, 6H), 8.10 (d, 2H, J=7.69Hz). 
 
Compound (D2)  
Yield 46 %; 1H NMR (200 MHz, CDCl3) δ 2.26-2.15 (m, 1H), 3.73-3.71 (m, 2H), 3.68 
(s, 3H), 4.39-3.86 (m, 2H), 4.54-4.50 (m, 1H), 6.88 (d, 2H, J=7.69Hz), 7.09-7.05 (m, 
2H), 7.25-7.21 (m, 3H), 7.35-7.32 (m, 5H), 7.46-7.42 (m, 4H), 8.06 (d, 2H, J=7.69Hz). 
 
Compound (D3)  
Yield 59%; 1H NMR (200 MHz, CDCl3) δ 3.63-2.65 (m, 1H), 3.09 (dd, 1H, J=14.90 
and 3.70 Hz), 3.3 (dd, 1H, J=14.70 and 7.60 Hz), 4.15 (d, 4H, J=6.59 Hz), 4.20 (AB 
quartet, 2H, J=14.10 Hz),7.94-7.62 (m, 16 H), 7.80 (d, 2H, J=7.69 Hz), 8.06 (d, 2H, 
J=7.69 Hz). 
 
Compound (D4)  
Purified by flash chromatography (CH2Cl2) (56% yield); 1H NMR (400 MHz) CDCl3: δ 
8.06 (d, J= 7.2 Hz, 2H), 7.68 (d, J= 8.4 Hz, 2H), 7.39 (td, J= 7.7, 1.0 Hz, 2H), 7.30 (d, 
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J= 7.6 Hz, 2H), 7.28-7.00 (m, 10 H), 4.35 (d, J= 14 Hz, 1H), 4.15 (d, J= 6.4 Hz, 2H), 
4.00 (d, J= 14 Hz, 2H), 3.28 (dd, J= 14.8, 8.0 Hz, 1H), 3.08 (dd, J= 15.4, 3.8 Hz, 1H), 
2.67 (m, 1H), 2.44 (m, 3H).   
 
 
 
Compound (D5)  
Purified by flash chromatography (CH2Cl2) (38% yield); 1H NMR (400 MHz) CDCl3: δ 
8.07 (d, J= 7.6 Hz, 2H), 7.69 (d, J= 8.8 Hz, 2H), 7.50-7.35 (m, 4H), 7.30-7.10 (m, 6H), 
7.13-7.04 (m, 2H), 4.33 (d, J= 14.4 Hz, 1H), 4.17-4.03 (m, 4H), 3.30-3.27 (m, 1H), 
3.25-3.08 (m, 1H), 2.53-2.52 (m, 1H). 
 
Compound (D6)  
Purified by flash chromatography (CH2Cl2) (20% yield); 1H NMR (400 MHz) CDCl3: δ 
8.05 (d, J= 7.6 Hz, 2H), 7.72 (d, J= 8.8 Hz, 2H), 7.38 (t, J= 7.6 Hz, 2H), 7.37-7.09 (m, 
7H), 7.04-6.80 (m, 4H), 4.32 (d, J= 14 Hz, 1H), 4.17-4.10 (m, 2H), 4.08-4.00 (m, 2H), 
3.87 (s, 3H), 3.29-3.23 (m, 1H), 3.08-3.03 (m, 1H), 2.71-2.70 (m, 1H). 
 
Compound (D7)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (60% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.10 (d, J= 7.6 Hz, 2H), 7.79-7.73 (m, 2H), 7.56-7.39 (m, 8H), 
7.29-7.15 (m, 4H), 6.91-6.87 (m, 2H), 4.45-4.31 (m, 3H), 3.41-3.04 (m, 3H), 2.76-2.51 
(m, 3H). 
 
Compound (D8) 
Purified by preparative HPLC (32% yield); 1H NMR (400 MHz) CDCl3: δ 8.08 (d, J= 
7.6 Hz, 2H), 7.57 (d, J= 8.4 Hz, 2H), 7.50-7.39 (m, 4H), 7.30-7.15 (m, 7H), 6.89 (d, J= 
7.6 Hz, 2H), 4.43-4.21 (m, 3H), 3.27-3.29 (m, 2H), 3.20-3.15 (m, 1H), 3.06 (d, J= 14 
Hz, 1H), 2.87-2.80 (m, 1H), 2.70-2.55 (m, 2H), 2.38 (s, 3H). 
 
Compound (D9)  
Purified by preparative HPLC (13% yield); 1H NMR (400 MHz) CDCl3: δ 8.10 (d, J= 
7.6 Hz, 2H), 7.60-7.53 (m, 2H), 7.50-7.40 (m, 6H), 7.39-7.15 (m, 5H), 6.92-6.87 (m, 
2H), 4.40-4.35 (m, 3H), 3.31-3.24 (m, 3H), 3.09 (d, J= 14 Hz, 1H), 2.70-2.60 (m, 3H). 
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Compound (D10)  
Purified by preparative HPLC (23% yield); 1H NMR (400 MHz) CDCl3: δ 8.10 (d, J= 
8.0 Hz, 2H), 7.62 (d, J= 7.2 Hz, 2H), 7.51-7.38 (m, 4H), 7.28-7.17 (m, 6H), 6.55-6.45 
(m, 2H), 4.43-4.21 (m, 3H), 3.84 (s, 3H), 3.32-3.23 (m, 2H), 2.74 (s, 1H), 2.70-2.56 (m, 
2H). 
 
Compound (D11)  
Purified by flash chromatography (100 to 90% Hexane/EtOAc) (37% yield); 1H NMR 
(200 MHz) CDCl3: δ 8.09 (d, J= 7.8 Hz, 2H), 7.80-7.27 (m, 2H), 7.56-7.42 (m, 6H), 
7.30-7.19 (m, 3H), 4.49-4.30 (m, 3H), 3.58-3.42 (m, 2H), 3.26-3.03 (m, 3H), 1.52-0.44 
(m, 10H). 
 
Compound (D12)  
Purified by flash chromatography (CH2Cl2) (42% yield); 1H NMR (400 MHz) CDCl3: δ 
8.08 (d, J= 7.2 Hz, 2H), 7.62 (d, J= 8.4 Hz, 2H), 7.50-7.43 (m, 4H), 7.26-7.20 (m, 4H), 
4.45-4.38 (m, 3H), 3.65-3.60 (m, 1H), 3.47-3.40 (m, 1H), 3.20-3.12 (m, 1H), 3.05 (d, J= 
15.6 Hz, 1H), 2.40 (s, 3H), 1.38-1.20 (m, 4H), 1.15-0.93 (m, 3H), 0.54-0.30 (m, 2H), 
0.22-0.15 (m, 1H). 
 
Compound (D13)  
Purified by flash chromatography (80% CH2Cl2/EtOAc) (28% yield); 1H NMR (400 
MHz) CDCl3: δ 8.09 (d, J= 7.6 Hz, 2H), 7.66 (d, J= 8.4 Hz, 2H), 7.50-7.40 (m, 6H), 
7.30-7.23 (m, 2H), 4.45-4.35 (m, 3H), 3.20-3.13 (m, 2H), 3.11-3.05 (m, 2H), 1.45-0.93 
(m, 7H), 0.57-0.24 (m, 3H). 
 
Compound (D14)  
Purified by flash chromatography (80% CH2Cl2/EtOAc) (30% yield); 1H NMR (400 
MHz) CDCl3: δ 8,08 (d, J= 8.0 Hz, 2H), 7.66 (d, J= 8.8 Hz, 2H), 7.50-7.45 (m, 4H), 
7.27-7.20 (m, 3H), 6.90 (d, J= 6.8 Hz, 2H), 4.45-4.35 (m, 3H), 3.84 (s, 3H), 3.65-3.60 
(m, 1H), 3.47-3.40 (m, 1H), 3.20-3.12 (m, 1H), 3.05 (d, J= 15.6 Hz, 1H), 1.45-0.93 (m, 
7H), 0.57-0.19 (m, 3H). 
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E SERIES 
 
Compound (42) 
Indole 41 (5g, 1 eq) was dissolved in DMF (70 ml) and KOH (1.2 eq) was added and 
cooled to 0°C. Then a solution of Epichlorohydrin (2.5 eq) in DMF (20 Ml) was added 
dropwise. After stirring at 0°C for 5 h the mixture reaction was quenched with water 
and ice and extracted with EtOAc. The organic phase was separated and evaporated in 
vacuo, and a yellow oil was obtained. Purification by flash chromatography (100% 
Hexane) afforded pure product 42 (54% yield). 
1H NMR (200 MHz) CDCl3: δ 7.65 (d, J= 7.5 Hz, 1H), 7.39 (d, J= 8.19 Hz, 1H), 7.28-
7.09 (m, 3H), 6.52 (dd, J=3.11, 0.73 Hz, 1H), 4.44 (dd, J= 15.3, 3.2 Hz, 1H), 4.19 (dd, 
J= 15.2, 5.12 Hz, 1H), 3.33-3.25 (m, 1H), 2.81 (ψ t, J= 4.2 Hz, 1H), 2.46 (dd, J= 4.6, 
2.6 Hz, 1H). 
 
Compounds (43-46) 
General procedure. Epoxide 42 ( 1 g, 1 eq) was dissolved in EtOH (10 ml), and amine 
(2 eq) was added. The reaction mixture was stirred at 65°C overnight. After complete 
reaction EtOH was evaporated in vacuo. 
 
Compound (43)  
Purified by flash chromatography (95 to 80% Hexane/EtOAc) (34% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.65 (d, J= 7.1 Hz, 1H), 7.37 (d, J= 8.0 Hz, 1H), 7.26-7.08 (m, 
5H), 6.75 (t, J= 7.32, 1H), 6.62 (d, J=7.6, 2H), 6.54 (d, J= 3.1 Hz, 1H), 4.34-4.07 (m, 
2H), 3.34-3.06 (m, 3H). 
 
Compound (44)  
Purified by crystallization with Et2O (60% yield); 1H NMR (200 MHz) CDCl3: δ 7.63 
(d, J= 7.3 Hz, 1H), 7.38-7.10 (m, 9H), 6.50 (d, J= 3.1 Hz, 1H), 4.46 (dd, J= 5.4, 1.0 Hz, 
2H), 4.10-3.97 (m, 1H), 3.74 (d, J= 3.8 Hz, 2H), 2.77 (dd, J= 12.1, 3.7 Hz, 1H), 2,51 
(dd, J= 12.1, 8.2 Hz, 1H). 
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Compound (45)  
Purified by crystallization with Et2O (78% yield); 1H NMR (200 MHz) CDCl3: δ 7.62 
d, J= 7.50 Hz, 1H), 7.36-7.09 (m, 9H), 6.50 (dd, J= 3.1, 0.73 Hz, 1H), 4.16 (d, J= 5.6 
Hz, 2H), 4.03-3.92 (m, 1H), 2.91-2.68 (m, 5H), 2.48 (dd, J= 12.0, 8.4 Hz, 1H). 
 
Compound (46)  
Purified by crystallization with Et2O (95% yield); 1H NMR (200 MHz) CDCl3: δ 7.62 
(d, J= 7.6 Hz, 1H), 7.37 (d, J= 8.2 Hz, 1H), 7.26-7.06 (m, 3H), 6.50 (d, J= 3.1, 1H), 
4.17 (d, J=5.6 Hz, 2H), 4.00-3.91 (m, 1H), 2.77 (dd, J= 12.0, 3.66 Hz, 1H), 2.46 (dd, 
J=12.0, 8.42 Hz, 1H), 2.31 (tt, J= 10.1, 7.3 Hz, 1H), 1.83-1.64 (m, 5H), 1.30-0.97 (m, 
5H). 
 
Compounds (E1-E14) 
General procedure. To a solution of amine (200mg, 1 eq) in CH2Cl2 (4 ml) Aryl-
sulfonyl chloride (1.1 eq), PS-DIEA (1.2 eq) and DMAP (cat.) were added. The reaction 
mixture was stirred overnight at room temperature and then filtered and evaporated in 
vacuo. 
 
Compound (E1)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (54% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.62-7.01 (m, 5H), 6.46 (d, J= 3.1 Hz, 1H), 4.43-4.31 (m, 1H), 
4.41-4.07 (m, 2H), 3.63-3.60 (m, 2H). 
 
Compound (E2)  
Purified by flash chromatography (90 to 85% Hexane/EtOAc) (75% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.59 (d, J= 6.9 Hz, 1H), 7.42-7.01 (m, 13H), 6.46 (d, J= 3.1 Hz, 
1H), 4.43-4.31 (m, 1H), 4.17-4.06 (m, 3H), 3.61-3.58 (m, 2H), 2.42 (s, 3H). 
 
Compound (E3)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (79% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.79 (m, 2H), 7.65-7.47 (m, 4H), 7.28-7.03 (m, 8H), 6.90 (d, J= 
3.1 Hz, 1H), 6.45 (d, J= 3.1 Hz, 1H), 4.38-3.81 (m, 4H), 3.15-3.04 (m, 2H), 2.49 (d, J= 
2.9 Hz, 1H). 
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Compound (E4)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (81% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.68-7.57 (m, 3H), 7.32-7.02 (m, 10H), 6.90 (d, J= 3.1 Hz, 1H), 
6.44 (d, J= 2.5 Hz, 1H), 4.35-3.79 (m, 4H), 3.12-3.04 (m, 2H), 2.52 (d, J= 14.6 Hz, 1H), 
2.44 (s, 3H). 
 
Compound (E5)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (71% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.69-7.59 (m, 3H), 7.49-7.43 (m, 2H), 7.29-7.03 (m, 8H), 6.91 (d, 
J= 3.1 Hz, 1H), 6.46 (d, J= 2.5 Hz, 1H), 4.35-3.88 (m, 4H), 3.13-3.05 (m, 2H), 2.41 (d, 
J= 2.5 Hz, 1H). 
 
Compound (E6)  
Purified by flash chromatography (95 to 85% Hexane/EtOAc) (5% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.69 (AA’XX’, J= 8.9, 5.0 Hz, 2H), 7.62-7.58 (m, 1H), 7.28-6.09 
(m, 11H), 6.45 (d, J= 3.1 Hz, 1H), 4.34-3.87 (m, 7H), 3.10-3.03 (m, 2H), 2.56 (d, J= 2.7 
Hz, 1H). 
 
Compound (E7)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (71% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.63-7.42 (m, 5H), 7.33-6.98 (m, 10H), 6.53 (d, J= 3.1 Hz, 1H), 
4.23-4.04 (m, 3H), 3.43-2.98 (m, 3H), 2.83-2.59 (m, 3H). 
 
Compound (E8)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (78% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.67-7.58 (m, 3H), 7.35-6.99 (m, 9H), 6.54 (d, J= 3.1 Hz, 1H), 
4.19 (bs, 3H), 3.54-2.97 (m, 3H), 2.77-2.65 (m, 3H), 2.42 (s, 3H). 
 
Compound (E9)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (56% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.62 (m, 3H), 7.42-6.98 (m, 11H), 6.54 (d, J= 3.1 Hz, 1H), 4.23-
4.14 (m, 3H), 3.35-2.99 (m, 3H), 2.81-2.56 (m, 2H). 
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Compound (E10)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (63% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.67-7.60 (m, 3H), 7.34-6.86 (m, 11H), 6.54 (d, J= 3.1 Hz, 1H), 
4.19-4.11 (m, 3H), 3.86 (s, 3H), 3.42-2.95 (m, 3H), 2.80-2.63 (m, 3H). 
 
Compound (E11)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (65% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.74 (m, 2H), 7.64-7.35 (m, 5H), 7.26-7.05 (m, 3H), 6.53 (d, J= 
2.5 Hz, 1H), 4.28-4.06 (m, 3H), 3.63-3.47 (m, 2H), 3.08 (d, J=6.2 Hz, 2H), 1.51-0.46 
(m, 10H). 
 
Compound (E12)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (84% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.62 (d, J= 8.0 Hz, 2H), 7.37 (d, J= 7.8 Hz, 1H), 7.27-7.05 (m, 
6H), 6.53 (d, J= 3.1 Hz, 1H), 4.28-4.05 (m, 2H), 3.62-3.51 (m, 2H), 3.06 (d, J= 6.2 Hz, 
2H), 2.41 (s, 3H), 1.58-0.45 (m, 10H). 
 
Compound (E13)  
Purified by flash chromatography (95% Hexane/EtOAc) (61% yield); 1H NMR (200 
MHz) CDCl3: δ 7.68-7.61 (m, 2H), 7.46-7.34 (m, 3H), 7.26-7-06 (m, 4H), 6.53 (d, J= 
3.1 Hz, 1H), 4.22 (s, 2H), 3.54 (tt, J= 11.8, 6.7 Hz, 1H), 3.36 (s, 1H), 3.06 (d, J= 5.4 Hz, 
2H), 1.55-0.55 (m, 10H). 
 
Compound (E14)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (72% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.70-7.06 (m, 3H), 7.37 (d, J= 8.2 Hz, 1H), 7.26-7.05 (m, 3H), 
6.95-6.88 (m, 2H), 6.52 (d, J= 3.1 Hz, 1H), 4.28-4.05 (m, 2H), 3.85 (s, 3H), 3.62-3.46 
(m, 2H), 3.05 (d, J= 6.22 Hz, 2H), 1.57-0.57 (m, 10H). 
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F SERIES 
 
Compound (48) 
1,2,3,4-Tetrahydrocarbazole (5g, 1 eq) was dissolved in DMF (70 ml) and KOH (1.2 
eq) was added and cooled to 0°C. Then a solution of epichlorohydrin (2.5 eq) in DMF 
(20 mL) was added dropwise. After stirring at 0°C for 5 h the mixture reaction was 
quenched with water and ice and extracted with EtOAc. The organic phase was 
separated and evaporated in vacuo, and a yellow oil was obtained. Purification by flash 
chromatography (100% Hexane) afforded pure compound 48 (75% yield). 
1H NMR (200 MHz) CDCl3: δ 7.4 (d, J= 8.2 Hz, 1H), 7.33-7.25 (m, 1H), 7.20-7.05 (m, 
2H), 4.3 (dd, J= 15.6, 3.5 Hz, 1H), 4.15 (dd, J= 15.7, 4.5 Hz, 1H), 3.25-3.18 (m, 1H), 
2.47 (dd, J= 4.7, 2.5 Hz, 1H), 2.01-1.81 (m, 4H). 
 
Compounds (49-50) 
Epoxide 48 ( 1 g, 1 eq) was dissolved in EtOH (10 ml), and amine (2 eq) was added. 
The reaction mixture was stirred at 65°C overnight. After complete reaction EtOH was 
evaporated in vacuo. The products were purified by flash chromatography. 
 
Compound (49)  
Purified by flash chromatography (90 to 70% Hexane/EtOAc) (37% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.48-7.43 (m, 1H), 7.36-7.20 (m, 6H), 7.19-7.03 (m, 2H), 4.12-
3.98 (m, 3H), 3.75 (d, J= 2.5 Hz, 2H), 2.82-2.55 (m, 6H), 2.0-1.80 (m, 4H). 
 
Compound (50)  
Purified by flash chromatography (100 to 70% Hexane/EtOAc) (55% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.47-7.43 (m, 1H), 7.33-7.01 (m, 8H), 4.15-3.19 (m, 3H), 3.19-
2.97 (m, 10H), 1.92-1.80 (m, 4H). 
 
 
 
Compounds (F1-F7) 
General procedure. To a solution of amine (200mg, 1 eq) in CH2Cl2 (4 ml) Aryl-
sulfonyl chloride (1.1 eq), PS-DIEA (1.2 eq) and DMAP (cat.) was added. The reaction 
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mixture was stirred overnight at room temperature and then filtered and evaporated in 
vacuo. 
 
Compound (F1)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (77% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.85-7.77 (m, 2H), 7.67-7.39 (m, 4H), 7.28-7.21 (m, 2H), 7.19-
6.94 (m, 6H), 4.23 (AB quartet, J= 40.5-14.1 Hz, 2H), 3.92-3.80 (m, 3H), 3.28-3.02 (m, 
2H), 2.68-2.59 (m, 2H), 2.58-2.33 (m, 3H), 1.87-1.79 (m, 4H). 
 
Compound (F2)  
Purified by flash chromatography (90% Hexane/EtOAc) (85% yield); 1H NMR (200 
MHz) CDCl3: δ 7.69 (d, J= 3.2 Hz, 2H), 7.46-6.90 (m, 11H), 4.20 (AB quartet, J= 46.8, 
14.2 Hz, 2H), 3.91-3.75 (m, 3H), 3.31-2.96 (m, 2H), 2.75-2.55 (m, 2H), 2.55-2.31 (m, 
3H), 2.44 (s, 3H), 1.93-1.67 (m, 4H). 
 
Compound (F3)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (10% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.78 7.65 (m, 2H), 7.53-7.40 (m, 3H), 7.32-7.20 (m, 3H), 7.20-
6.90 (m, 5H), 4.22 (AB quartet, J= 25.6, 14.2 Hz, 2H), 4.00-3.75 (m, 3H), 3.30-2.98 (m, 
2H), 2.79-2.60 (m, 2H), 2.57-2.40 (m, 2H), 2.40-2.25 (m, 1H), 2.00-1.70 (m, 4H). 
 
Compound (F4) 
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (10% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.87-7.68 (m, 2H), 7.47-7.35 (m, 1H), 7.35-6.90 (m, 10H), 4.47-
4.00 (m, 2H), 4.00-3.70 (6H), 3.30-2.95 (m, 2H), 2.75-2.60 (m, 2H), 2.60-2.40 (m, 2H), 
2.00-1.70 (m, 4H). 
 
Compound (F5)  
Purified by flash chromatography (100 to 90% Hexane/EtOAc) (97% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.76-7.02 (m, 2H), 7.43-7.16 (m, 4H), 7.28-6.98 (m, 10H), 4.22-
4.00 (m, 3H), 3.41-3.01 (m, 4H), 2.83-2.56 (m, 6H), 1.94-1.72 (m, 4H). 
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Compound (F6)  
Purified by flash chromatography (100 to 90% Hexane/EtOAc) (93% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.61 (d, J= 8.2 Hz, 2H), 7.49-7.45 (m, 1H), 7.28-6.97 (m, 10H), 
4.20-4.02 (m, 3H), 3.42-2.99 (m, 4H), 2.82-2.57 (m, 6H), 2.41 (s, 3H), 1.97-1.75 (m, 
4H). 
 
Compound (F7)  
Purified by flash chromatography (100 to 90% Hexane/EtOAc) (69% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.60 (d, J= 8.4 Hz, 2H), 7.50-7.38 (m, 3H), 7.28-6.98 (m, 10H), 
4.22-4.06 (m, 3H), 3.41-3.01 (m, 4H), 2.84-2.60 (m, 6H), 2.03-1.80 (m, 4H). 
 
G SERIES 
 
 
Compound (42)  
Prepared as previously described for E series. 
 
Compound (48)  
Prepared as previously described for F series. 
 
Compound (51) 
Commercially available 2,3-diphenyl indole (5g, 1 eq) was dissolved in DMF (70 ml) 
and KOH (1.2 eq) was added and cooled to 0°C. Then a solution of epichlorohydrin (2.5 
eq) in DMF (20 Ml) was added dropwise. After stirring at 0°C for 5 h the mixture 
reaction was quenched with water and ice and extracted with EtOAc. The organic phase 
was separated and evaporated in vacuo, and a yellow oil was obtained. Crystallization 
from Et2O afforded the desired compound 51 (48% yield).  
1H NMR (200 MHz) CDCl3: δ 7.81 (d, J= 7.6 Hz, 1H), 7.54 (d, J= 8.05 Hz, 1H), 7.42-
7.17 (m, 2H), 4.26 (d, J= 4.39 Hz, 2H), 3.21-3.13 (m, 1H), 2.72 (ψ t, J= 4.39 Hz, 1H), 
2.36 (dd, J= 4.76, 2.56 Hz, 1H). 
 
Compounds (G1-G3) 
General procedure. Epoxides 42, 48, 51 ( 1 g, 1 eq) was dissolved in EtOH (10 ml), 
amine (2 eq) and BiCl3 were added. The reaction mixture was stirred at 65°C overnight. 
After complete reaction EtOH was evaporated in vacuo. 
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Compound (G1)  
Purified by flash chromatography (95 to 80% Hexane/EtOAc) (55% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.80 (m, 2H), 7.66 (d, J= 7.8 Hz, 1H9, 7.50-7.10 (m, 8H), 6.62-
6.50 (m, 2H), 4.66 (s, 1H), 4.45-4.24 (m, 3H), 3.51-3.43 (m, 2H), 3.28 (dd, J=12.7, 6.8 
Hz, 1H), 2.21 (s, 1H). 
 
Compound (G2)  
Purified by flash chromatography (95 to 80% Hexane/EtOAc) (57% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.83-7.74 (m, 2H), 7.59-7.56 (m, 2H), 7.48-7.18 (m, 16H), 6.40-
6.36 (m, 1H), 4.44-4.33 (m, 2H), 4.36-4.28 (m, 1H), 3.26 (dd, J= 12.5, 3.7 Hz, 1H), 
3.08 (dd, J= 12.7, 6.4 Hz, 1H). 
 
Compound (G3)  
Purified by flash chromatography (95 to 90% Hexane/EtOAc) (25% yield); 1H NMR 
(200 MHz) CDCl3: δ 7.89-7.73 (m, 2H), 7.60-7.09 (m, 8H), 6.5 (dd, J= 6.7, 1.6 Hz, 
1H), 4.82-4.63 (m, 1H), 4.57-4.35 (m, 1H), 4.27 (d, J= 6.2 Hz, 2H), 3.50 (dd, J= 12.4, 
3.1 Hz, 1H), 3.34 (dd, J= 12.4, 6.9 Hz, 1H), 2.93-2.53 (m, 4H), 2.10 (d, J= 3.4 Hz, 1H), 
2.04-1.62 (m, 4H). 
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